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Introduction; Acute respiratory distress syndrome (ARDS) is a major cause of
death on intensive care units. The syndrome is characterised by severe hypoxia,
widespread atelectasis and decreased lung compliance, much of this impairment due
to depletion and inhibition of surfactant. Therapy is supportive. For research
purposes, many of the features of ARDS may be mimicked by a saline lavage model
of lung injury.
Perfluorocarbons have many characteristics similar to natural surfactants and have
been used as an experimental means of supporting the injured lung, applied either by
special liquid ventilators or as a hybrid technique with conventional gas ventilators
known as partial liquid ventilation. Although nebulization is an accepted means of
drug delivery, Perfluorocarbons had never been applied by a nebulized route to
support the injured lung.
Surfactant therapy has also been used to support the lung in the presence of ARDS.
Surfactant preparations can be split into two broad categories; artificial surfactants
containing no surfactant proteins and natural, but more expensive protein containing
surfactants. There may be additional benefits of combining surfactant with
Perfluorocarbons.
Methods; This study examined the differences between saline lavaged lung injured
rabbits, in the following treatment groups;
i) control,
ii) partial liquid ventilation i.e. poured perfluorocarbon PF 5080;
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iii) nebulized PF 5080,
iv) the artificial surfactant Pumactant used in isolation,
v) the natural porcine surfactant Curosurf used in isolation,
vi) Pumactant used in combination with partial liquid ventilation and
vii) Curosurf used in combination with partial liquid ventilation.
The following end points were examined;
a) Survival in saline lavaged rabbits to 12 hours,
b) Differences in oxygenation between the treatment groups to 6 hours,
c) Differences in dynamic compliance between the treatment groups to 6 hours, and
static compliance between control, the Pumactant and the Curosurf groups,
d) The appearance of computed tomography densities between the control, nebulized
and partial liquid ventilation groups in frozen, ex- vivo lung preparations.
Results; Survival to twelve hours in this study was greatest in the partial liquid
ventilation alone or the combination of Pumactant with partial liquid ventilation.
Oxygenation was improved by partial liquid ventilation, the natural surfactant
Curosurf, or the combination of either Pumactant, or Curosurf with partial liquid
ventilation.
Dynamic compliance improved after partial liquid ventilation, Curosurf in isolation
or the combination of Curosurf with partial liquid ventilation.
Static compliance improved after treatment with Curosurf but not after treatment
with Pumactant.
There was a significant difference in density distributions in the CT scanning studies
between the partial liquid ventilation and nebulized perfluorocarbon, and the control
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and partial liquid ventilation groups, but not between control and the nebulized
groups implying little perfluorocarbon is delivered to the lungs by this route.
Comments; In summary PF 5080 can be used for partial liquid ventilation in this
model of lung injury to improve survival, oxygenation and lung mechanics. Using
this method, nebulization of PF 5080 cannot be supported as it seems to have little
effect on these end-points and may not be delivered in any significant amount to the
respiratory tract.
Curosurf is superior to Pumactant in improving oxygenation, and lung mechanics in
this model of acute lung injury. There seems to be little difference between Curosurf
and poured PF 5080 in terms of these endpoints.
Whether partial liquid ventilation becomes more widespread in the support of the
injured lung will depend on further research applications including means of
application and trials in humans.
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The acute respiratory distress syndrome (ARDS) is a major cause of death in
• • 9
intensive care practice. The syndrome has an incidence in the United Kingdom of
4.5 cases per 100 000 population and in the same study accounted for 2.5% of ITU
(intensive therapy unit) admissions. This may be an underestimate. The clinical
course is variable, but once on the ITU patients with ARDS represent a significant
workload, as the mean duration of mechanical ventilation is 10-14 days, whilst 10-
20% of these patients remain ventilator dependent for more than 3 weeks .
The multiplicity of underlying causes has led to a wide range of quoted mortality of
10-90%4, although a frequently quoted mortality is 50-60% 4'5. Prognosis is
worsened by risk factors such as advanced age, pre-existing diseases and sepsis 5.
If one accepts a mortality of approximately 50-60%, then the mortality for this
syndrome has remained essentially unchanged since Ashbaugh et al's original
description in 1967 6. Krafft et al found no trend towards a reduction of mortality
over time in 16 major studies encompassing a total of 1790 patients between 1979
and 1994 4. Milberg et al found rather more cause for optimism in his group's
analysis of their institute's survival rates for ARDS between 1983-1993, particularly
the latter years of this study and in those less than 60 years old and with sepsis
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syndrome as their cause for ARDS7. The exact reason for this recent reduction in
mortality is unclear.
Be that as it may, ARDS, although rare in the population overall, represents a
considerable burden to intensive care units, and a patient diagnosed as having
"ARDS" has a substantial chance of dying of this condition.
Definition of ARDS
One reason for this variable mortality may have been the laxity of definition of
ARDS. In broad terms, ARDS is characterised by hypoxaemia, pulmonary oedema
due to leakage from pulmonary capillaries which appears as infiltrates on chest
radiograms, and poorly compliant lungs, associated with certain underlying
conditions. Most commonly these other conditions are sepsis syndrome, aspiration,
primary pneumonia and multiple trauma 8.
In an attempt to standardise definitions for the purposes of epidemiology and future
clinical trials, an American-European consensus conference on ARDS, held in
October 1992 defined ARDS more exactly at the severe end of an acute lung injury
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spectrum as follows ;
i) the timing of ARDS must be acute and persistent, lasting days to weeks. The acute
lung injury/ARDS must be associated with one or more known risk factors,
characterised by arterial hypoxaemia resistant to oxygen therapy alone and
associated with diffuse radiologic infiltrates;
ii) there must be an impairment of oxygenation defined as a Pa02/Fi02 < 200mmHg;
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iii) a pulmonary artery wedge pressure < 18 mmHg when measured, or no clinical
evidence of left atrial hypertension.
Although associated with several underlying conditions such as multiple trauma or
sepsis, the exact cause of ARDS remains unknown. There is therefore no known
single point in the disease process where one might successfully intervene and
consequently treatment remains supportive.
Respiratory Supportive Strategies
Previous supportive respiratory strategies had strived assiduously to achieve
"normal" arterial partial pressures for oxygen and carbon dioxide9.
Unfortunately this supportive strategy can cause damage in its own right. In order to
achieve a normal PaC>2 or PaCC>2, tidal volumes of 10-15ml/kg body weight were
used. In the presence of diseased lungs, with poor general compliance, high airway
pressures had to be used in order to generate these large tidal volumes. This pressure
induced damage (barotrauma) may be seen in the most extreme circumstances as
pneumothorax, pneumomediastinum, pneumopericardium and bronchiolar rupture,
but also more subtly as pulmonary interstitial emphysema, perivascular
haemorrhage, and perialveolar haemorrhage l0.
There is however evidence to suggest that the damaging factor is not so much
pressure per se but the forcing of too great a volume into the lungs (overdistention) -
so called "volutrauma 11 ;12. This volutrauma during mechanical ventilation has been
termed ventilator induced lung injury (VILI)13 14.
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Ventilator Induced Lung Injury (VILI)
As mentioned above, mechanical ventilation can itself damage the lungs. There has
been a recent growing body of evidence that modes of ventilation which lead to
repeated opening and closing of airways and large pressure amplitudes,15 not only
cause lung parenchymal damage but may also promote inflammatory mediator
production and bacterial translocation from the lung. This may contribute to multiple
1 ^ ••
system organ failure . The corollary of this is that means of supporting ventilation
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which limit derecruitment and overdistention of lungs may be less damaging
and may demonstrate a reduced inflammatory response 1819and possibly reduced
mortality 20.
There have been a number of concepts to deal with these problems of abnormal lung
mechanics, complicated by ARDS representing a non-homogenous disease 21.
Gattinoni et al22 described the acutely injured lungs as consisting of three zones;
zone H (healthy) representing normal lung; zone R (recruitable) representing
atelectatic lung which could be opened up by therapeutic manoeuvres such as
positive end-expiratory pressure (PEEP) to become functional lung units once more,
and zone D (diseased) which were resistant to such therapeutic manoeuvres. Those
areas of lung which are atelectatic do not allow areas of gas exchange and represent
shunt, and hence significantly contribute to hypoxaemia. Thus if one considers the
amount of actual lung available for gas exchange, which may be as little as 20-30%
79 19
of total units, it is as if the patient has a "baby" or shrunken lung ; .
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Positive End-Expiratory Pressure (PEEP)
PEEP increases transpulmonary pressure and increases lung volume at end-
• • 23
expiration i.e. increases functional residual capacity (FRC). This reduces shunt. .
PEEP also helps reduce formation of pulmonary oedema in various ways e.g. by
haemodynamic effects 24 such as reducing cardiac output25. An appropriate amount
of PEEP i.e. neither too little nor too much, may also prevent damage to surfactant
27. In addition to improving gas exchange and decreasing pulmonary oedema, PEEP
will oppose tidal opening and collapse of distal airways, lessening lung injury and
may decrease release of inflammatory mediators and cytokines from the injured
lung. 13
Elowever PEEP may have undesired effects such as the previously mentioned
decrease in cardiac output (by limiting venous return)25 ;28 and it has been associated
with barotrauma 29. So although some PEEP may be desirable, too much may be
harmful30.
Several methods have been used to try to determine optimal or "best PEEP".
Methods used have included;
a) lung mechanics, i.e. the PEEP which gives the maximum improvement in total
• • T1
static compliance ,
b) PEEP which reduces shunt fraction to less than 15% of the cardiac output ,
c) the setting which permits the reduction of inspired oxygen tensions to minimal
levels (consistent with acceptable oxygenation)
d) the level which demonstrates the greatest recruitment of lung units on CT imaging
34
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Some of the strategies above present significant risks or logistical problems.
Gallagher et al's adherence to increasing the PEEP to ensure a reduction in shunt
fraction to less than 15% of cardiac output, no matter which level that may be,
resulted in some spectacularly high PEEP settings 32. In a case series of 59 patients
requiring greater than 10 cm H2O of PEEP (range 15-65 cm H2O) with a mean of 27
(standard deviation 7 cm H2O). They quote an incidence of pneumothorax of 10% in
their series. Certainly a PEEP level of 65 cm H2O would seem to be against current
opinion of aiming to keep end-inspiratory static (plateau) pressures of less than 30-
40 cm H20 35.
Gattinoni's group used CT scanning as a means of monitoring the effect of PEEP 34.
This is obviously not a test that can be performed at the bedside, and requires that
patients with often perilous oxygenation status be transferred to CT scanners.
A consensus opinion based on lung mechanics and recommended by the American-
European Consensus Conference on ARDS was a total PEEP which obliterated the
lower inflexion zone (Pflex) of the inspiratory static pressure volume curve of the
TS • • •
respiratory system , representing the re-opening of collapsed areas of lung. This
attempted to ensure near complete recruitment and the consensus was that this was a
level of 10-15 cm H2O in most instances. In terms of recruiting more alveoli by
increasing mean alveolar pressure, there was no consensus as to whether the best
means to do this was by adding more PEEP or by extending inspiratory time. They
made the general comment that the least mean airway pressure should be used which
accomplishes acceptable arterial oxygenation at a non-toxic concentration of
inspired oxygen (implying this might be an F1O2 of 0.65, although without
specifically stating what acceptable oxygenation was) 3\
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One question could be where best to apply PEEP? In another CT scan study,
Gattinoni's group examined the effect of the distribution of tidal volume and
l/r #
recruitment of lung tissue in patients with ARDS . This study looked at the various
regional (ventral to dorsal) effects of PEEP with varying plateau pressures (i.e. end
inspiratory pressures), whilst keeping the tidal volume constant. They found that
increasing PEEP decreased the tidal volume distribution to the most ventral (non-
dependent) portions of the lung, whilst significantly increasing the tidal volume to
the dorsal (dependent) parts of the lung. This finding they explained as the
worsening of compliance in the ventral parts of the lung as these non-dependent
portions were increasingly overstretched, coupled with the improving compliance as
atelectatic areas in the most dependent parts of the lung were held open. Increasing
plateau pressures increased recruitment ventrally to dorsally, but no difference was
seen between plateau pressures of 21 through to 46 cm H2O. Their third conclusion
was that increasing PEEP from 0 to 20 cm H2O increased lung recruitment ventrally
to dorsally.
These findings should be taken in conjunction with the findings of the same group
from the CT scanning study in 1993 which demonstrated that the hydrostatic
pressure of oedematous overlying lung can cause compression atelectasis in the most
dependent parts of the lung which may be eliminated by applying an appropriate
amount of PEEP 34.
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In short, in ARDS some PEEP is needed in the most dependent (most atelectatic)
sections of the lung. But a consequence of the heterogeneity of the injured lung is
that what is an adequate amount of PEEP for the atelectatic regions may cause
overdistention in the non-dependent or healthy regions of the lung. There is therefore
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a very great risk of overdistention of these areas of lung . Furthermore, the forcing
of a tidal volume intended for the whole lung, into an area of only 20% of the whole
lung may lead to overdistention and ventilator induced lung injury (VILI).
What would be ideal is a mode of maintaining end-expiratory pressure in a graded
manner applying it preferentially where it is most needed.
Prior attempts at applying these respiratory supportive strategies in clinical practice
have been varied. Aside from PEEP (as mentioned above), investigators have tried
permissive hypercapnia (in an attempt to limit the size of tidal volume and
consequently the degree of overdistention of the lung) ; High Frequency Ventilation
(HFV)38 and extracorporeal lung assist39'40 in an attempt to rest the lung.
None had shown undisputed reductions in mortality. The failure of traditional
ventilatory strategies to prevent end-expiratory collapse may have contributed to
lung injury41 and interfered with the surfactant system in the lungs 27 42.
Alveolar Surface Tension and the Role of Surfactant
Even under normal circumstances, surface tension arises at the gas/ alveolar fluid
interface. This is because the forces between adjacent molecules of the fluid lining
the curved surface of the alveolus are much greater than those between the liquid and
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gas interface. This forces the liquid surface area to be as small as possible43. Thus
the surface of a "bubble" (for bubble read alveolus) forms a sphere which is the
smallest surface area of the bubble for a given volume. The surface tension generates
a pressure which could be predicted from the Law of Young and Laplace 44'45.
The Law of Young and Laplace45
AP= 2y/r
where p= pressure; y= surface tension; r= radius
In plain English this means if surface tension, particularly in small alveoli, were not
reduced, pressure within these alveoli would rise, which would force gas out of these
alveoli into neighbouring lower pressure (larger) alveoli, making these small alveoli
smaller still. A vicious circle of alveolar collapse would ensue46.
Under normal circumstances surfactant lowers the surface tension within alveoli at
the gas/ fluid interface. This is because phospholipid molecules in surfactant,
particularly DiPalmitoyl Phosphotidyl Choline (DPPC) have hydrophobic acyl
chains orientated towards the gas, and hydrophilic polar portions orientated towards
the liquid surface 47. These molecules align along the alveolar surface. As the
alveolus becomes smaller towards the end of expiration, the intermolecular repulsive
forces of the phospholipids oppose the normal forces of attraction between the
surface molecules responsible for surface tension43. During surface compression the
phospholipids consisting mostly of DPPC forms a rigid monolayer 47. So alveoli are
maintained open and stabilised by the presence of surfactant.
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Additionally any group of alveoli which develop a tendency to collapse will to some
extent be held open by the stable surrounding alveoli- so called interdependence43'4 .
A factor contributing to the generally poor compliance of the lungs in ARDS is the
deficiency in endogenous surfactant function 49 44 50.
Surfactant also keeps the alveoli relatively dry. In a similar way that surface tension
has a tendency to collapse alveoli, there is also a tendency for surface tension to suck
fluid from the interstitium into the alveoli. By reducing surface tension this tendency
is reduced43'45. Hill postulates that there may be a "water repellency" component i.e.
that surfactant forces fluid into pockets or "pools" within the alveoli from which the
fluid is returned to the interstitium51. Others claim the traditional view52, that there is
a lining layer of liquid, deeper in some areas such as at comers on which the
surfactant sits, and that the surfactant reduces surface tension. This helps to balance
forces such as the hydrostatic pressure in the alveolar liquid layer. It is
acknowledged however that there is some evidence for both the traditional and Hill's
view52.
A summary of some of the functions of pulmonary surfactant is shown in Table 1 45.
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Table 1 A summary of some of the functions ofpulmonary surfactant.
Biophysical functions of surfactant
Prevents collapse of the alveoli and lungs during expiration.
Supports inspiratory opening of the lungs.
Prevents lung oedema formation by balancing hydrostatic filtration forces.
Stabilises and keeps small airways patent.
Improves mucociliary transport.
Translocates particles <6microns into the hypophase of the epithelial lining fluid,
and facilitates removal of particles and cellular debris from the alveoli into the large
airways.
Immunological, nonbiophysical surfactant functions.
Phospholipids suppress proliferation, immunoglobin production and cytotoxicity of
lymphocytes, and also inhibit endotoxin stimulated cytokine release from
macrophages.
SP-A & SP-D modulate phagocytosis, chemotaxis and oxidative bursts of
macrophages.
Neutralization of endogenous mediators like radicals and reactive oxygen species.
SP-A & SP-D opsonize various micro-organisms for easier phagocytosis
Binding and capture of bacterial toxins by SP-A and SP-D.
Thus surfactant helps both keep alveoli patent and reduces the pressure required to
re-expand them, and consequently work of breathing 44'53- Furthermore endogenous
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surfactant reduces alveolar lung water, and may have an important role in
deactivating inflammatory mediators, and have cytoprotective properties 54.
Normal Structure and Metabolism of Surfactant
Structure
Surfactant is normally produced by the type II pneumocytes in the lungs, and is
composed of the following major components; neutral lipids (mainly cholesterol
which constitutes 6-8% of total lipids) and phospholipids (80-90% of total lipids, the
majority of which (75%) is DiPalmitoyl Phosphatidyl Choline -DPPC). The other
major phospholipids are phosphotidylglycerol (10%), phosphotidylethanolamine
(5%), phosphotidylserine and phosphotidylinositol (5%) with less than 5%
sphingomyelin. There are also four different surfactant specific proteins called SP-A,
SP-B, SP-C and SP-D 47;55 4S.
The surfactant components are stored in multilayered membraned bodies known as
lamellar bodies in the Type II pneumocytes. After secretion they are converted to a
lattice like tubular lipid double layer called tubular myelin (vide infra in Metabolism
section; see Figure 1)44;47. Tubular myelin is the main intra-alveolar reservoir of
surfactant. It may be that the surface film is also formed by intra-alveolar membrane
structures47. For formation of these structures and for transitions to occur between
them other surfactant components, particularly the surfactant proteins are required47.
SP-A is a hydrophilic highly glycosylated multimeric protein weighing
approximately 650kD. SP-A binds phosphatidylcholine, and is felt to promote
formation of myelin like tubules as well as promoting adsorbtion. It is also thought
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to be involved in the release of surfactant from type II pneumocytes and in
immunoregulation within the lung44 45.
SP-B and SP-C are hydrophobic and help in the adsorbtion and spreading of
surfactant at the gas-liquid interface. They also constitute some degree of resistance
to inactivation in the presence of acute lung injury 56 47.
SP-D is a hydrophilic protein composed of four subunits each of approximately 43
kiloDaltons in molecular mass. Its functions are less well understood. It is thought to
contribute little to the surface active properties of surfactant, but may enhance the
production of oxygen radicals in alveolar macrophages and may have a role in the
host defences of the lung 47.
Metabolism44'47;
Surfactant phopsholipid is synthesised in the endoplasmic reticulum of Type II
pneumocytes, before being transferred to the lamellar bodies prior to secretion via
the Golgi complex (see Figure 1 which depicts a schematic representation ofmajor
pathways of surfactant phospholipids metabolism). Surfactant proteins are also
produced in the endoplasmic reticulum, but are transferred to the lamellar bodies via
multivesicular bodies. The lipid and protein components of surfactant are first fused
in the lamellar bodies. Secretion of surfactant into the alveoli seems to be regulated
by several factors including increased ventilation, acetylcholine, B2 agonists and
prostaglandins. There may even be a feed-back mechanism associated with SP-A.
During inspiration spreading of phospholipids from tubular myelin must occur
rapidly in order to spread over the expanding surface. The composition of
phospholipids may help, the unsaturated phospholipids being squeezed out leaving
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only a stiff DPPC monolayer behind. This process may be enhanced by surfactant
proteins, particularly SP-B and SP-A (in the presence of SP-B).
The monolayer thus formed has a turnover time variously cited as approximately 3-
11 hours, though some cite clearance of surfactant from the alveolar space to occur
with a half-life of approximately 20 hours53.
Surfactant lipids and proteins are removed by alveolar macrophages and the more
important route of re-uptake into Type II pneumocytes. Whether the phospholipids
are further degraded is unclear, as is the exact means of recognition of these
phospholipids and proteins by macrophages and Type II cells.
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Figure 1. Schematic representation of major pathways of surfactant
phospholipid metabolism44
Type II Pneumocyte Alveolus
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Pulmonary Surfactant in the Presence of Acute Lung Injury.
The importance of an adequate amount of normally functioning surfactant was
illustrated as long ago as 1959 by Avery and Mead who highlighted the respiratory
distress syndrome of the newborn 46. Although a differing syndrome from ARDS,
there were many similar features, including reduced lung compliance,
intrapulmonary shunting, atelectasis and decreased functional residual capacity.
Indeed abnormalities of surface tension of minced lungs at autopsy were recorded in
Ashbaugh et al's original description of ARDS6.
The exact nature of the deficit in acute lung injury/ARDS is unclear. There is
evidence of an absolute deficiency of total surfactant57, refuted by others 58 39. The
poor function of surfactant in the face of ARDS may be due to the presence of
inhibitors 59 50 or abnormally constituted surfactant 49 58. Despite these differences
(perhaps due to varying experimental models and extraction techniques), as Holm
and Matalon note, the surfactant system is in some way compromised, and although
this may not be the primary pathogenic factor this should not imply that the effect on
the surfactant system is merely of secondary importance53. Any surfactant
deficiency, whatever its underlying nature, will have an important role in the
pathophysiology of acute lung injury, and attempts to rectify this deficiency warrant
further investigation.
Surfactant therapy for infants requiring mechanical ventilation for respiratory
distress syndrome has been standard therapy since 1990 60.
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However, studies assessing the effects of surfactant in adult human acute lung injury
have been few 61 62'63 and there had been no direct comparisons between
preparations of apoprotein containing surfactant (such as Curosurf) and non-
apoprotein containing surfactants (such as Pumactant) in adult human ARDS.
The few attempts at trying to rectify this deficit by administration of exogenous
surfactant in humans have to date been disappointing ' , although there have been
procedural criticisms of these studies. There are only two randomised controlled
trials of surfactant administration to patients with ARDS; Anzuetto et al for The
Exosurf Acute Respiratory Distress Syndrome Study Group, and Gregory et al.
The Exosurf Acute Respiratory Distress Syndrome Study Group
These investigators administered Exosurf, a synthetic surfactant consisting of
predominanatly dipalmitoylphosphatidylcholine, and free of apoproteins, to 364
patients (361 controls) with ARDS due to sepsis. They found no statistically
significant difference between treated and control groups in terms of oxygenation,
duration of mechanical ventilation, length of ITU stay or survival at 30 days.
The calculated average administered dose of Exosurf was 112mg/kg body weight
per day (which may in its own right be inadequate) but further admitted that as little
as 4% of the nebulized dose could have actually reached the lungs.
The authors also acknowledged that the lack of apoprotein could have contributed to
the drug's apparent lack of effect.
They also recognised that ARDS may be the respiratory manifestation of a systemic
upset, and that Exosurf was only treating one component of that disorder.
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One point mentioned in the methodology, but not stressed in the discussion was the
large amount of saline in which the surfactant was dissolved. The dilution was
13.5mg DPCC to 1ml 0.45% saline. Thus, assuming the average administered dose
of 112mg/kg/day this would mean 8.3ml/kg/day of 0.45% saline applied to the lungs
(or approximately 530ml in a 70 kg patient). It is easy to imagine that this would
have a deleterious effect in a patient who already has precarious oxygenation.
The Bovine Surfactant Beractant (Survanta) in Patients with Acute Respiratory
Distress Syndrome .
These investigators studied the effect of the bovine surfactant, Beractant in a
randomised prospective controlled open-labelled clinical study to obtain preliminary
information with regard to safety and efficacy. Survanta, the form of Beractant
produced by Abbott Laboratories, in addition to containing phospholipids, acid
lipids and fatty acids, also contains surfactant proteins B and C. The study was
design to determine whether this preparation given early in the course of ARDS
could alter PaCVFiOi, decrease peak inspiratory pressure and decrease PEEP, and
increase the quasistatic pulmonary compliance. There were 4 groups totalling 59
patients; control; a group who received 8 doses of 50mg/kg; a group who received 4
doses of lOOmg/kg; and a group who received 8 doses of lOOmg/kg. The doses were
based on previous animal work. Administration of Beractant was made via a catheter
inserted into the endotracheal tube just proximal to the carina. F1O2 was decreased at
120 hours only for the group treated with 4 doses of lOOmg/kg. The group
administered 1 OOmg/kg for 8 doses showed more cardiovascular system failure on
day 2, thought to be due to the volume of surfactant administered. They concluded
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that the results were encouraging and were good justification for further multi-centre
trials.
Requirements of a Supportive Therapy in Acute Lung Injury/ ARDS
Thus if one were describing the required properties of a means of ventilatory support
for the acutely injured lung, this description may be as follows;
i) in the first instance as an absolute sine qua non it must be able support gas
exchange i.e. oxygen must be delivered to the blood and carbon dioxide (CO2)
removed from it;
ii) it must make the optimum use of available gas exchange units, by recruiting
atelectatic areas;
iii) it must not contribute to iatrogenic lung damage i.e. gas exchange must be
achieved with the minimum of volutrauma/ barotrauma to the lung;
iv) it should go some way to rectifying the abnormalities of surface tension caused
by the change in lung surfactant;
v) it should alter the progression of the natural history of the disease
vi) it should be non-toxic.
Although these points are contentious, there is evidence that many of these
requirements are fulfilled by liquid ventilation , more specifically by partial liquid
ventilation with perfluorocarbon(s) [PFC] 64-67.
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Review of Liquid Ventilation
The ability to sustain mammalian respiration through a liquid medium is generally
accredited to Kylstra et al who described the total immersion of mice using
/- o
hyperbaric salt solutions . The hyperbaric conditions were required so that
sufficient oxygen could be dissolved to sustain cell respiration. As an illustration, a
few of these mice were subjected to pressures of 160 atmospheres, equivalent to
ambient pressure 1 mile below the surface of the sea.
Unfortunately many of these animals died from what was thought to be respiratory
acidosis due to the increased work of breathing.
Clark and Gollan described total immersion techniques of cats and mice but at
atmospheric pressures 69. The agents used were either perfluorocarbons (PFC) or
silicone oils. The silicone oils proved to be too toxic for use with living tissues. This
left only the PFC, which remain the only agents available for use in this method of
respiratory support in either animal models or human subjects.
The Perfluorocarbons
The perfluorocarbons (PFC) are organic compounds in which the hydrogen ions
have been replaced by halogens (predominantly fluoride ions). The common
production techniques are electrochemical fluorination, by heating the organic
• • 70
product with cobalt trifluoride or careful direct fluorination with gaseous fluoride .
Non medical uses of PFC include their use as cooling fluids, insulators and as
constituents for products of the cosmetic industry. They were originally developed
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during the production of the atomic bomb, in an attempt to find agents which would
71 *79
not react with the unstable uranium isotopes ' .
They have also found medical applications as contrast agents during magnetic
resonance scanning, as sensitising agents during radiotherapy, and as possible
intravenous oxygen carrying agents 73"75. The presence of the fluoride ion makes the
compound more radio-opaque.70
Possible Modes of Action
PFCs are potentially of use in liquid ventilation as they are stable inert compounds
which do not react with living tissues. Although immiscible both with hydrophobic
and hydrophilic fluids, they can dissolve large quantities of gases. As a general rule,
gas solubility in a PFC decreases in the order CO2 » oxygen> carbon monoxide>
nitrogen. Linear PFCs such as Perflubron are said to dissolve oxygen more
effectively than cyclic PFCs such as Perfluorodecalin 76. However oxygen solubility
is also inversely proportional to the molecular weight and directly related to the
number of fluorine ions present76. It should be stressed that oxygen solubility in
PFC is purely a passive process unlike the binding and release of oxygen to
haemoglobin in the blood.
There is an inverse relationship between vapour pressure of a PFC and molecular
• 7S
weight i.e. the lower the molecular weight, the higher the vapour pressure .
Some examples of PFCs which have been used for liquid ventilation are shown in
Figure 2. Their physical properties are shown in Table 2. As can be seen, many of
the characteristics are fairly similar such as molecular weights (416-499 Daltons),
oxygen solubility (approximately 50ml of oxygen per 100ml of PFC, when
equilibrated against 100% oxygen at 25 °C) and carbon dioxide solubility
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(approximately 200ml CO2 per 100ml PFC at 1 atmosphere pressure and at body
temperature).
Furthermore, PFC have a low surface tension approximately 12-18 dyne/cm, and
may to some extent compensate for deficient surfactant function. The low surface
• 77
tension is due to weak intermolecular forces of the PFC .
PFC are nearly twice as dense as water, and if applied to the lungs will gravitate to
the most dependent parts of the lung. This function has been compared to the
application of PEEP (which some investigators have termed "PEEP in a bottle"),
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where PEEP is needed most, that is in the collapsed, dependent areas of the lung
Rf) •
. This may be a means of optimising ventilation and perfusion.
Indeed optimisation of ventilation/ perfusion matching, diverting blood away from
dependent poorly ventilated alveoli has been suggested to be one reason why
• ••• •• ••81
oxygenation improves with liquid ventilation in lung injury . However liquid
ventilation does not improve oxygenation in normal mammals82. It has also been
suggested that this is due to interference with (the already optimal) V/Q matching,
• • • RT
increased shunt and possibly diffusion impairment .
Despite high density, PFC have a viscosity similar to water.
They have also been said to reduce the inflammatory response to lung injury 84 85.
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Figure 2
Structure of Selected Perfluorocarbons
FC 3280/ Also the structure of PF 5080 (C8F18)
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Structure of Perflubron and Perfluorodecalin 72. Structure of PF 5080, FC
3280, FC 75 and FC 11, data on file with Company, (3M Chemical Group,
Zwijndrecht, Belgium). Structure of RlMAR 101, data on file with Company
(Miteni SPA, Vicenza, Italy).
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Choice of Perfluorocarbon
Theoretically, to be useful for partial liquid ventilation, a PFC should possess the
following properties; it should have the ability to contain sufficient amounts of
dissolved oxygen and carbon dioxide at body temperature. It should have a lower
surface tension than the surface tension of injured lungs (often cited as 20-25
dyne/cm) 6 53.
It should be denser than body tissues, so that it will sink to the most dependent
regions of the lung but not so viscous that the resistance of the fluid in the airways
becomes problematic 65, or that CO2 removal is inhibited. The CO2 removal problem
can to some extent be compensated for by the ability to dissolve very large amounts
of C02 86.
The boiling point and saturated vapour pressure are characteristics important for a
number of reasons. A low boiling point and consequently high saturated vapour
pressure means that the PFC will evaporate off quickly, and therefore require more
frequent replenishment (with cost and labour implications). However as the main
route of elimination for PFC used in liquid ventilation is by evaporation 70 75 64, it
will be eliminated from the lungs more quickly when the process of weaning from
partial liquid ventilation is required. A balance of these two facets is therefore
required.
With regard to this thesis, surface tension and viscosity have a bearing on the ease of
ultrasonic nebulization. The lower the surface tension, the more drug can be
delivered; the greater the viscosity, the less drug can be delivered 87. However, at the
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time of designing this study there was no readily available information on how any
specific PFC would behave when nebulized for treating lung injury.
The PFC should be non-toxic, safe and from a practical point of view be readily
obtainable and cheap.
Until recently the only PFC licensed for (human) use as a medium to support
respiration by the Food and Drug Administration in the United States is Perflubron,
the tradename of which is LiquiVent ® (Alliance Pharmaceutical Corporation, San
Diego, USA). The access to this agent is restricted to a small number of centres, and
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1.78 1.77 1.78 1.95 1.93 1.76 1.76
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*Data on file 3M Belgium NM, Zwijndrecht, Belgium. Remainder of table
RIMAR 101 88.
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Application of the liquid medium.
As mentioned above, the early experimentation with liquid ventilation involved the
total immersion of small animals. For larger animal models of liquid ventilation an
extracorporeal circuit was required (see Figure 3).
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Figure 3
Schematic Representation of a Liquid Ventilator (for Total Liquid Ventilation)
From Hirschl et al
89
Key
A= Heat Exchanger/ Membrane Oxygenator and Oxygen inlet
B= Animal connected to an endotracheal tube and extracorporeal circuit
C= Pinch valve connected to timer and occlusive roller pump
D= Reservoir
E= Occlusive roller pump
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This was connected to the respiratory tract via an endotracheal tube. The lungs were
then filled to functional residual capacity (FRC) and tidal volumes of liquid
introduced during an "inspiratory" phase and let out of the lungs during an
"expiratory" phase. This method where the lungs are filled to FRC and then
ventilation is conducted with tidal volumes of liquid is known as total liquid
ventilation 88:90 89 91.
In the ensuing thirty years, work has continued on the use of liquid ventilation in a
number of animal models, utilising normal, premature and lung injured animals 92 93
70;94 95
The major disadvantages of this technique are that it requires complex and expensive
pieces of apparatus such as an extracorporeal circuit 96 89. Additionally the
extracorporeal circuit itself has had developmental problems, particularly the
tendency of the expiratory valve to jam.
Fuhrman et al described the first use of partial liquid ventilation in 1991, although
this group called the technique perfluorocarbon associated gas exchange (PAGE)82.
This was a hybrid technique combining filling the lungs of normal piglets to FRC
with the perfluorocarbon FC 77, but superimposing gaseous tidal volumes with a
standard mechanical ventilator upon this.
Liquid Ventilation in Humans
The first human use of a liquid ventilation technique had been by Greenspan et al in
1989 97. This was however not strictly partial liquid ventilation, as Greenspan's
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description was in a 28 week gestation neonate who had her (failing) standard
ventilation interrupted to allow 2 three minutes periods of total liquid ventilation
(separated by 15 minutes). This was achieved with an ad hoc apparatus allowing
drainage of oxygenated PFC into the lungs from a burette suspended above the
patient. Then gas ventilation was resumed. The lungs had been filled to FRC
(30ml/kg) then ventilated with 15ml/kg liquid tidal volumes allowing gravity
assisted drainage into a vessel below the patient. Each tidal volume was held within
the lungs for 15 seconds and the patient was "ventilated" with a liquid respiratory
frequency of 2-3 "breaths" per minute. There was a sustained increase in PaC>2 and a
decrease in PaCCE which was maintained for about 2 hours post procedure. There
was an accompanying increase in compliance and a reduction in airways' resistance.
Despite this the patient died 19 hours later.
The same centre reported this patient along with two others in a case series in 1990,
QO t #
who were ventilated using a similar technique . All were 23-28 weeks gestation in
whom conventional therapy for severe respiratory distress had failed. Although all
died within 19 hours, it was felt that this reflected the severity of the underlying lung
disease before initiation of liquid ventilation, and demonstrated the potential of this
treatment for pulmonary dysfunction in the pre-term neonate.
Partial Liquid Ventilation (PLV)
The first recorded use of partial liquid ventilation in humans is accredited to Hirschl
et al who described their experience of PLV in a group of 19 mixed adult, paediatric
and neonatal patients ". This was an uncontrolled study to evaluate the safety and
efficacy of PLV. These patients were being supported with extracorporeal lung assist
(ELA) and so had the back up of an extracorporeal means of oxygenation and
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removing CO2 should there have been a deterioration of respiratory function on
initiation of PLV. During periods off ELA, the patients demonstrated an
improvement in alveolar-arterial oxygen difference and also an improvement in
static pulmonary compliance. Fourteen of the patients were successfully weaned
from ELA and eleven survived, which was the expected survival for patients who
were so gravely ill. Causes of death were cited as irreversible lung disease (4
patients), cerebrovascular accident (1 patient), ischaemic encephalopathy after
cardiac arrest (1 patient), and multi-organ failure (2 patients). The authors concluded
that, "partial liquid ventilation can be safely used in patients with severe respiratory
failure and may improve lungfunction^.
Papers have subsequently been published describing PLV in adult 10°, paediatric 101
and neonatal practice in a population of premature infants with respiratory distress
syndrome 102.
There are currently a number of phase III trials of PLV in ARDS being conducted in
North America and Europe.
There had been no studies at the time of originally drafting this thesis investigating
the efficacy of introducing PFC into the respiratory tract for the purposes of partial
liquid ventilation by means of nebulization.
Potential Problems with Partial Liquid Ventilation.
Pneumothorax
Hirschl et al's described pneumothoraces in 9 of their 19 patients ". However, 6 of
these patients had had pneumothoraces prior to initiation of partial liquid ventilation.
It is therefore difficult to differentiate the side effect of the treatment from a known
association of the disease. Despite this, the suspicion of an association between PLV
/
and pneumothorax persists. Verbrugge and Lachmann give a number of
explanations for this 66. At end expiration alveoli will collapse if insufficient PEEP
is applied. This may be as "gas" PEEP or "liquid" PEEP. If insufficient gas PEEP is
applied to support the non-PFC filled alveoli, shear force will cause pneumothorax.
Secondly, with regard to this level of gas PEEP, the gas PEEP required will depend
on the disease state of the individual alveolus. In those alveoli unable to reduce
surface tension to less than the PFC (usually PFC used for liquid ventilation have
surface tensions of approximately 15-18 dyne/cm-see Table 2) the level of gas PEEP
required during PLV will be less than required during conventional ventilation.
However in those alveoli with a still functioning surfactant system, coating the
alveolus with a thin layer of PFC with a higher surface tension than the "healthy"
alveolus will necessitate an increase in PEEP for these areas.
Another problem with PLV is uncertainty as to where the gas is actually going. If the
gas is going to those parts of the lung not fully filled with liquid this could cause
severe lung overdistention and may result in a high rate of pneumothorax. It is
therefore suggested by these authors that "fluid PEEP" i.e. PLV be combined with
pressure controlled modes of ventilation in which the pressure level in any alveolus
should never exceed the pressure level set on the ventilator to prevent dangerous
alveolar overdistention.
Haemodvnamics;
Filling the thorax to approximately functional residual capacity with a dense, non -
compressible fluid may reasonably be expected to have major effects on the
circulation.
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Evidence from Houmes et al103 showed that there were no deleterious effects on the
circulation even when large animals (sheep) with an average thoracic antero¬
posterior diameter of 24 cm were filled with a total of 25ml/kg Perflubron. Several
reasons were postulated why this theoretical worry should prove less of a problem in
practice.
Some of the earlier studies suggesting that there was haemodynamic compromise
were in TOTAL liquid ventilation models i.e. where there was an uninterrupted
column of dense PFC. This does not happen with PARTIAL liquid ventilation.
Indeed some investigators go as far as to say that "PLV has no known side effects on
the cardiovascular system" 64.
One might also have worried that a dense incompressible fluid may increase
pulmonary vascular resistance (PVR) and strain on the right side of the heart. Effects
upon PVR may in fact be a balance of deleterious and positive effects. On the
negative side, the PFC may compress blood vessels increasing pulmonary arteriole
pressure and resistance. Set against this is the reduction in hypoxic pulmonary
vasoconstriction caused by better oxygenation.
Lactic Acidosis 104
Despite studies indicating generally well preserved haemodynamic status, a
metabolic acidosis has been noted in some animal studies94 104. This has been
ascribed to changes in regional organ blood flow during mechanical ventilation with
positive end-expiratory pressure, even if general global cardiovascular status was
maintained. However, this has by no means been universally reported 103. This may
be due to redistribution of blood flow 105 or an ineffective vascular volume I06.
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Weaning back to gaseous ventilation.
Many researchers report successful re-conversion to gaseous ventilation after a
period of liquid ventilation 90. However a temporary impairment of arterial
oxygenation which took up to several days to return to pre-liquid breathing levels
has also been noted 90 107. This effect has been subscribed to residual PFC remaining
in the lungs, causing a diffusion defect, low ventilation/ perfusion areas or
decreasing alveolar PaC>2. Reversible changes in lung mechanics have been noted
after liquid ventilation 108 107.
As a net amount of PFC is allowed to evaporate off and is not replaced during the
conversion phase from liquid to gaseous ventilation, it may be necessary to increase
PEEP to prevent atelectasis109. This is to compensate for the loss of the fluid bulk of
PFC helping to splint open the alveoli at end expiration.
A worrying fact is that occult pneumothoraces may only become obvious when PFC
is allowed to evaporate .
Interpretation of Standard Chest Radiograms
The development of occult pneumothoraces underscores the point that the
radiodensity of PFC may hinder interpretation of radiograms. Although said to be
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mostly a problem with radiodense atoms such as iodine and bromine , even PFC
which do not contain these atoms may hinder interpretation of x-rays. As an
example, a plain chest film of a rabbit undergoing PLV with PF 5080 (CsFis) and a
control rabbit are shown towards the end of this thesis (Figure 22).
Blocking of the Endotracheal Tube
Hirschl's group reported mucous plugging in one of their 19 patients which
compromised gas exchange and required aggressive suctioning and bronchoscopy
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This would be in keeping with the finding reported later in the same paper that
exudate in the peripheral airways and alveoli could be effectively lavaged to the
central airways whence it could be removed by suctioning.
CCb clearance
Ineffective elimination of CO2 was particularly a problem with inadequate settings
of total liquid ventilators 90 108. The difficulty has been ascribed to the high viscosity
of PFC compared with gas together with the low CO2 diffusion coefficient. This
problem could be reduced by choosing the appropriate (total liquid) ventilator
settings .
Elimination and Toxicity
This problem may be largely theoretical. The studies looking at the metabolism of
PFC record slow clearance from the body. Elimination even when administered
intravenously is largely via the lung and little if any metabolism takes place.
Perfluorocarbons are however taken up by the reticular endothelial system.74.
Reports of perfluorochemicals used as intravenous oxygen carriers cite half-lives of
as long as 500 days 75. Even when applied only to the respiratory tract, traces have
been found three years after a 1 hour exposure to liquid ventilation. Admittedly there
seems to be no inflammatory reaction to these substances which are regarded as
innocuous and chemically inert 75, and the authors of the paper which found trace
amounts present three years later still concluded that the PFC (Caroxin-F) could "be
breathed without residual deleterious effects" no. Others have found no effects on
the function of surfactant when extracted from dogs five days after exposure U1.
This should also be set against a background of the high mortality of ARDS i.e. a
high chance of death in the next few hours to days compared with an unproven
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theoretical risk of an indeterminate side effect years in the future. However there is
caution in using agents which may be retained in the body for so long even if they
appear to do no harm.
Nebulization
Nebulization is an accepted means of delivery for agents such as the B2 agonists,
steroids, ribavirin and surfactants 112;113114. Could it be an effective means of
delivery for PFC, compared to a similar dose poured into the respiratory tract?
If the administration of PFC is to translate from the laboratory to clinical practice, it
must be seen to have practical benefits. The practical clinical advantage of being
able to administer PFC by a method (i.e. nebulization) more readily familiar to staff
working on an intensive therapy unit is obvious. If the nebulized route were found to
be equally effective as pouring PFC into the respiratory tract, it could allay fears
about cardiovascular compromise due to a thorax full of PFC impairing venous
return 10s, even if some would argue that these fears are unfounded 103.
There are three commonly used methods of introducing nebulized agents into the
respiratory tract; pressurised Metered Dose Inhalers (pMDI), jet nebulizers and
ultrasonic nebulizers 112. Factors felt to influence the efficacy of delivery are the
presence of a holding chamber, siting on the inspiratory limb of a ventilator, absence
of humidity and reducing the respiratory rate to increase inspiratory time, all of
which increase delivery to the subject.
There had been no previous attempts at trying to administer PFC to the lungs as a
means of respiratory support. Pressurised metered dose inhalers consequently were
not produced for PFC and jet nebulizers may upset the settings of mechanical
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ventilator. In terms of this study, if PFC were to be delivered to the respiratory tract
by a nebulized technique, then this would have to be done by means of a ultrasonic
nebulizer. There is also the theoretical benefit of delivering a greater dose if this
technique is used.
As mentioned above, there was no information available on optimal nebulizer
settings specifically for PFC use in ARDS. There was also no information on the
distribution pattern of PFC used therapeutically in ARDS. As a general theoretical
comment, in order to deposit the PFC in the alveoli, the settings on the ultrasonic
nebulizer should be chosen to deliver particles less than 5 microns. Larger than this
87
may result in the droplets being deposited in the larger conducting airways .
Radiographic imaging and ARDS
Traditionally radiographic assessment of patients with ARDS has been done by
portable chest radiograms 6;115. There are however problems with this means of
assessment. Poor patient mobility and lack of co-operation combined with limited
access due to presence of equipment on the ICU has reduced the quality of films.
Also, the requirement to use a portable x-ray apparatus is associated with several
problems. The poorer power output of these portable units means that longer
exposure times must be used (which causes movement artefact). There is also the
well documented problem of apparent magnification of the heart due to the shorter
film-to-focus distance and the antero-posterior projection of the supine patient.
Consistency of film exposure is therefore difficult. Attempts to circumvent this
problem have been made with storage phosphor technology. The incident energy is
trapped in the phosphor plate as a latent image. This is then subsequently read by
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laser, and the detected signal transformed by an analogue-to-digital converter to
digital data. This can be presented in a format which resembles a conventional film,
but with the advantages that there is a reliable consistency of optical densities
between serial films and the ability to post process films and enhance difficult areas
115
The radiological-pathological co-relations of ARDS can be thought of as follows;
Stage 1 (0-24 hours post initiating cause) in which there is early exudation of fluid
but may be "silent" by standard radiographic techniques.
Stage 2 (24-36 hours post initiating cause) is where fluid leakage into the
interstitium and alveolar space becomes more obvious with alveolar collapse. There
may be a "ground glass" appearance to the chest x-ray.
Stage3 (c. 72hours onwards) histologically the fibrotic process starts and this may
begin to manifest itself as persistence of the ground glass appearance with reticular
shadowing 115.
Computed Tomography in ARDS
Computed Tomography (CT) imaging measures radiographic density of small
discrete parts of the body (pixels) displayed as two dimensional images. The
radiographic density is measured in Hounsfield Units (HU) and is represented by
varying shades of grey; less dense images (air -1000 HU) are black through to the
most dense media (e.g. bone, +1000 HU) which are white. Thus each CT image is a
collection of small squares each with a discrete "grey" value which represents the
mean radiographic density of a 3 dimensional cylinder/ volume of tissue called a
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voxel 116;117. Dense tissue adjacent to or within the lung may influence this average
density ("partial volume effect").
CT imaging of the thorax is becoming an increasingly routine investigation in
patients with ARDS with the advent of fast scanners. It has been used extensively to
help in the understanding of the pathophysiology 34'117 of ARDS as well as detecting
lesions which would have been missed using standard x-rays such as abscesses
emphysema and mediastinal disease, and occult pneumothorax115. CT scanning has
been vital in underscoring the non-uniform heterogenous nature of ARDS, with
patches of uninvolved lung interspersed with areas involved with ARDS.
However CT imaging of the lung during liquid ventilation is limited to only a few
118-121
papers " , and has not been used to compare the distribution patterns of poured
versus nebulized PFC in partial liquid ventilation.
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Purpose of the Project
I had previous research experience of partial liquid ventilation in a porcine model of
ARDS while I had been a visiting Research Fellow at the Virchow Klinik in Berlin
(1995/6) ll9;I22;123.1 wished to consolidate this experience with a further research
project. The only PFC approved by the FDA for use as a partial liquid ventilation
agent at the time of drafting this project (late 1997) was Perflubron, but this was
only available to a few centres. The PFC of which I had previous personal
experience in Germany, FC 3280 (3M Chemicals, Bracknell, Berks, UK) had ceased
to be produced by the time I was preparing the early planning of this study.
However, a similar compound produced by 3M, and called PF 5080 had many
similar characteristics to agents such as Perflubron (see Table 2) and FC 3280, and
was readily available to me. Thus I chose PF 5080 as the liquid medium which had
both reasonable physical characteristics and a ready source of supply.
A second intent was to compare the efficacy of nebulized PFC to a similar dose
which was poured into the respiratory tract. The nebulized route is of course well
used for administration of drugs such as Beta2 adrenergic agonists on intensive
therapy units. However by 1997, it had never been used as a route of administration
for the study ofpartial liquid ventilation. If nebulization were to prove an equally
efficacious way to apply PFC as pouring PFC it would have a major benefit in
translating this into clinical practice. That is, most ITU staff are familiar with
nebulized drugs; most are not familiar currently with (partial) liquid ventilation.
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There is less potential for causing lung damage. The simplicity of administration
would make the therapy more widely available. All these statements have
subsequently been recognised 124.
The primary outcome measure was to be short-term survival (to twelve hours), with
secondary outcome measures of gas exchange and lung mechanics, where
obtainable.
There are superficial similarities between some of the properties of surfactants and
PFC. However, as they may work by differing means, I therefore wished to see if any
additional benefit of short-term survival, gas exchange and lung mechanics could be
obtained by combining PF 5080 with surfactant. As the efficacy of the surfactant
used may depend on its ability to withstand inactivation, could a difference in effect
be seen between an expensive apoprotein containing surfactant and a substantially
cheaper artificial apoprotein free surfactant? I chose to compare the apoprotein
containing surfactant Poractant-alpha, more commonly known by its tradename
Curosurf (Serono Laboratories, Welwyn Garden City, UK which cost approximately
£334 per lOOmg at the time of the project) with the apoprotein free surfactant,
Pumactant (Britannia Pharmaceuticals Limited, Redhill, UK produced under the
tradename, ALEC, which cost approximately £150 per lOOmg). These were
preparations available at the time in the UK, and for which I had managed to obtain
a supply.
Curosurf is a natural porcine surfactant containing polar lipids mainly
phosphatidylcholine which constitutes 70% of total phospholipid content and circa
1% specific low molecular weight hydrophobic proteins SP-B and SP-C. Pumactant
is a 7;3 mixture by weight of Dipalmitoyl Phosphotidylcholine (DPPC) and
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unsaturated Phosphotidylglycerol (PG) 125.1 chose to administer lOOmg/kg, to be
free from the criticism of having underdosed the subjects. This dosage has been used
commonly in other studies investigating surfactantl26;127 128 1;129"131 132.
The concept of combining the surfactant preparations was based on a number of
premises. As mentioned above, as there may be a number of mechanisms of action
for both PLV and surfactants used in lung injury, their use may be additive. Further,
surfactants are expensive, PFC relatively cheap. The cost of 1 kilogramme of PF
5080 (568ml) was approximately £30 from 3M Chemicals, Bracknell, Berks, UK.
Could the combination of PFC/ surfactant show an additive effect? PFC may have a
"surfactant sparing" effect i.e. cause a small dose of (expensive) surfactant to go a
long way.
Furthermore, the project would allow the direct comparison of a less expensive
surfactant protein free preparation (Pumactant) to be compared with an expensive
surfactant protein containing preparation (Curosurf).
In addition to investigating the potential difference in mortality, gas exchange and
lung mechanics parameters between poured and nebulized PFC, the effect of these
modes of administration on the distribution of PF 5080 were examined on CT
scanning of the excised lungs. Therefore arrangements were made to perform CT
scanning of the excised lungs of 3 groups of animals; viz 10 controls, 6 poured PFC
and 10 nebulized PFC. These numbers were chosen to minimise the use of animals
in each group. These lungs were frozen in liquid nitrogen immediately post excision.




The main end points for this study were intended to be the survival, oxygenation,
compliance and CT scanning data. Due to the suspected difference in survival times
between treatment groups (which subsequently proved well founded) histology was
never intended to be a primary outcome, as it could be argued that a difference seen
in animals who died several hours after inducing lung injury, compared with animals
who died shortly after inducing lung injury was merely due to the effects of the
prolonged mechanical ventilation. In order to compare like with like, one would
have to choose a separate arm of the study in which all the groups were repeated but
the animals were killed at (for example) 2 hours i.e. at a time when significant
numbers of the animals in all treatment groups would be expected to still be alive.
As one of the basic tenets of this project was to study the effects of longer term
survival (to twelve hours- the maximum allowed under Home Office regulations),
then this would have meant effectively doubling the size of this project i.e. a study as
conducted with seven treatment groups to observe the parameters above to twelve
hours, and an additional study with the same seven study groups terminated shortly
after inducing lung injury purely for the purpose of obtaining histological data. This
would have exceeded the budget available from the funding bodies. It was however
suggested by the funding bodies that some limited histological analysis be done so
that evidence of lung injury is demonstrated. This was discussed with members of
the Pathology Department of Edinburgh University. There was some debate as to
how best to prepare the rabbit lungs including whether simple en-bloc dissection and
immersion in formalin be performed, as used in some studies including Lachman's
original work 110.122,133-135^ Qr wjjether infusion of formalin through the lungs via the
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pulmonary artery post mortem, but prior to excision should be conducted as cited by
or. i
others ' . Another consideration was which groups should be studied. For
simplicity I was advised to undertake the former i.e. block dissection and immersion,
and was finally advised that samples should be taken from the control group only (as
the purpose of this histological examination was merely to ascertain that the method
above of saline lavage and mechanical ventilation establishes lung injury). Final
analysis was done by another member of the Directorate of Pathology Edinburgh
University Medical School (Dr William Wallace) to whom I am extremely grateful.
The details of the histological examination, and pictures of haematoxylin and eosin
slides are shown from representative samples (taken from the control group) in
Chapter 3. This is to demonstrate that lung injury has occurred in animals subjected
to the saline lavage and mechanical ventilation in the conditions used in our
laboratory, and as representation of what the lungs would have look like should no
active treatment have been given. Further conclusions regarding the effects of the
various treatments upon lung histology are outwith the scope of this project, for the
reasons just given. These conclusions should not be drawn from this project, but
perhaps should be considered in later studies specifically designed to investigate the
histological effects of PF 5080 on lung injury.
Thus the lungs were preserved post autopsy either in liquid nitrogen (for the CT
scanning studies), and stored at -70°C (10 control animals, 10 animals treated with
nebulized PF 5080, and six animals treated with poured PF 5080) or 10% buffered
formalin (all other animals, including a further 6 treated by poured PF 5080).
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Statistical Analysis and Power Calculation
The statistical package used for this project was GraphPad Prism™ Version 2.0 and
4.0 (GraphPad Software Inc., San Diego, California, USA). Normally distributed
data were analysed between the groups using Analysis of Variance (ANOVA). The
test for goodness of fit to a normal distribution was the Kolmogorov-Smirnov test
available on this program, using Dallal and Wilkinson's approximation to Lilliefor's
method 137;138. Data which did not correspond to a normal distribution were analysed
using the Kruskal-Wallis test. Survival data were illustrated with Kaplan-Meier
survival curves and analysed using the Logrank test139;14°. Further details are given
in the individual chapters. Sample size and power calculations were performed with
the aid of the computer program PS Power and Sample Size Calculations (Copyright
1997 by W.D. Dupont and W.D. Plummer) I41;142.
Power Calculations for the Project
The accepted chance of a type I error (false positive) was the conventionally taken 1
in 20 (i.e. P<0.05). The accepted chance of a type II error (false negative) was the
conventionally taken chance of 0.2 (thus power of the test 1-0.2 = 0.8) 143;l44.
Information for power calculations was sought from references in the published
literature at the time of planning the project, and tried to draw upon references using
rabbits, and the saline lavage model of lung injury. Only Mrozek et al's reference
had compared combinations of surfactant and PLV in treatment groups of 8 animals
(saline lavaged rabbits) l45. These researchers however had no untreated controls.
Evidence from this paper suggested that in order to detect a difference in
oxygenation between surfactant alone (the bovine surfactant Survanta) and the
combination of Survanta and PLV (with Perflubron) of 13.4kPa (standard deviation
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± 7.2kPa) there would have to be 6 animals in each treatment group (assuming
P<0.05 and power of 0.8). Calculations were made using the computer program PS
Power and Sample Size Calculations.
With regard to changes in lung compliance (and again assuming P<0.05 and power
of 0.8) Mrozek's researchers 145 found a significant difference in compliance
between Survanta alone and Survanta combined with PLV of 0.26 ml/cml-bO
(standard deviation ± 0.11 ml/cmffO), in favour of the combination. This suggested
that I would have to have a minimum of 4 animals in each group to detect a
difference with the Type I and Type II errors quoted above.
Survival data were harder to assess. The conventional assessment of power for a
survival study would be based upon the median survival time 146 147 14°. However no
previous study had studied the survival of saline lavaged rabbits to 12 hours, in the
context of partial liquid ventilation. There were thus no median survival values
quoted. Other surrogate guidelines were taken. Kaisers et al using a saline lavage
porcine model, showed a significant improvement in survival comparing PLV to
control. There were six animals in each group. Survival times for the control group
were 0.1-4 hours (mean 1.8 hours ±1.4 SD.) compared to a range of 4-16 hours (8.2
hours ± 4.5 SD) for the treatment group filled to half functional residual capacity
with FC 3280 122.
Final Size of Treatment Groups.
Taking a combination of the survival, blood gas and lung mechanic results in the
available literature, as well as allowing for the originally intended differing
histological preparations, and with a small arbitrary but feasible safety margin, it was
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decided that the study should consist of 20 control animals, 12 PLV animals and 10
animals in each of the other treatment groups.
Thus the arms of the study were as follows;
1) Control (10 animals); formalin preparation at autopsy,
2) Control (10 animals); liquid nitrogen preparation at autopsy, then CT scanning,
3) Partial Liquid Ventilation i.e. poured PFC (12 animals); (6 animals post mortem
liquid nitrogen preparation then CT scanning; 6 animals post mortem 10% buffered
formalin preparation),
4) Nebulized PFC (10 animals); liquid nitrogen preparation then CT scanning,
5) Pumactant surfactant (10 animals);
6) Curosurf surfactant (10 animals);
7) Pumactant and poured PFC (10 animals);





This chapter will describe the methodology used during this project. It will include a
description of the model of lung injury chosen, as well as descriptions of the
important pieces of monitoring apparatus.
Mode of Experimental Lung Injury
Various species of animals have been used in the study of lung injury. They include
rat 132, rabbit 84;114;14g;1495 cat? dog, sheep and pig 88 150 119d23;i5i;i52 just a§ varjabie js
the variety of methods used to induce lung abnormality or induce lung injury such as
application of acid 153 154 directly into the respiratory tract, or the induction of lung
injury by the injection of an intravenous agent such as oleic acid91 136 155 I56. Septic
models of ARDS have used infusions of endotoxin 151 152.
These methods are all effective but some may result in a speciously severe lung
injury, perhaps causing death within 2 hours of initiation.
A further possibility of inducing lung injury is by saline lavage. A saline lavage
model of lung injury in the rabbit seemed to offer excellent reproducibility and
stability, not merely depleting the lung of surfactant, but also initiating some of the
early inflammatory changes of acute lung injury. This has been used as an
established means of causing lung injury for some decades 148 133 and has been cited




pathophysiological changes (to ARDS) . Lewis & Jobe quoted saline lavage as
not just causing surfactant depletion but also neutrophil influx, atelectasis, alveolar
damage and hyaline membrane formation 44, all changes seen in ARDS 157. Lewis
and Jobe also cite lavage as " a convenient way to cause consistent lung injury
across species " for factors such as "modes ofsurfactant delivery, distribution
patterns ofexogenous surfactants andphysiologic responses to different delivery
techniques The saline lavage model has been shown to produce acute hypoxaemia
in an otherwise haemodynamically stable animal. Thus any haemodynamic
instability seen within treatment groups may reasonably be attributed to a factor
associated with the treatment group itself133;148;152.1 had also had practical
experience of a (porcine) saline lavage model while I was a Research Fellow in
Germany 122 119;I23.
At the time of planning the study, there had been no comparative study comparing
saline lavage against acid instillation, intravenous infusion of endotoxin or oleic acid
infusion.
A study published subsequently by Rosenthal et al in 1998152 compared saline
lavage with hydrochloric acid instillation, endotoxin infusion or oleic acid infusion.
They found that instillation of HC1 or saline lavage resulted in significant
hypoxaemia but no cardiovascular instability. Endotoxin infusion did not result in
hypoxaemia, but caused significant decreases in systemic mean arterial pressure and
significant increases in pulmonary artery pressure and pulmonary vascular
resistance. Oleic acid infusion caused marked hypoxaemia, a pronounced increase in
mean pulmonary artery pressure and pulmonary vascular resistance, as well as a
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markedly reduced systemic mean arterial pressure, cardiac output and mixed venous
PO2. None of the four methods however in this study caused a significant increase in
the cytokine Tumour Necrosis Factor. So each of these various methods had
advantages and disadvantages, and none perfectly mimics ARDS.
I wanted to study the effects of PFC upon the lung, and while acknowledging that
ARDS does not often occur as an isolated lung injury, I did not want the
confounding elements of an unnaturally severe systemic upset. Furthermore, the
intended study was designed to see if there was any effect on the respiratory factors
contributing to short term mortality. Inducing a falsely severe lung injury which may
kill the animals within 1 -2 hours would not allow these respiratory factors to be
detected. I wanted to reflect an animal model of reasonable size without the species
become too cumbersome, and hence chose the rabbit.
In short, saline lung lavage is an accepted means of inducing acute lung injury, of
which I already had practical experience.
Methodology for the Study
A total of 82 young adult female New Zealand white rabbits (weight range 2.31-
4.27 kg; mean 3.46kg; standard deviation ± 0.40kg) were studied during these
investigations. Anaesthesia was induced with 6ml/kg over 5 minutes using a 25%
solution of the long acting anaesthetic/analgesic agent urethane. On veterinary
advice a repeat dose of 3ml/kg was administered 7 hours later to those animals still
alive. A tracheostomy was fashioned with a 3.0 mm internal diameter plain
endotracheal tube, while the animals were supine and breathing spontaneously. The
endotracheal tube was tied tightly to prevent any gas leakage round the tube. A bolus
of the neuromuscular blocking agent pancuronium was administered (0.2mg/kg) and
70
an infusion of pancuronium commenced at O.lSmgkg-'hour"1. An infusion of
maintenance fluids was also administered (7ml kg"'hour-1 of 0.45%saline/5%
dextrose). A 4 French gauge carotid artery catheter and internal jugular venous
catheter were inserted for measurement of arterial and venous pressures.
Additionally these cannulae facilitated obtaining arterial blood gas samples (via the
arterial line) and administration of fluid or drugs (in the case of the central line).
An SLE 250 paediatric pressure controlled, time cycled ventilator was used for all
experiments (Specialised Laboratory Equipment, Croydon, Surrey, UK). This was a
ventilator readily and freely available to me. All animals were ventilated in the
supine position, with an inspiratory oxygen fraction (F1O2) of 1.0. Initial ventilator
settings were chosen to be similar to settings used in previous studies of lung injury
induced by saline lavage in the rabbit104;122;158. The settings were; the pressure limit
was set to generate a tidal volume of lOml/kg, measured by a Ventrak 1550
respiratory mechanics monitoring system (Novametrix Medical Systems,
Wallingford, Connecticut, USA), with an initial respiratory rate of 30 breaths per
minute. The duration of the inspiratory phase was 1 second (Ti 1.0). Four
centimetres water pressure of PEEP (4cm FLO) were applied as standard.
Baseline haemodynamic variables (Mean Arterial Pressure, CVP, heart rate where
obtainable) were obtained as were respiratory variables (tidal volume, respiratory
rate, mean airway pressure, total respiratory system dynamic compliance, arterial
blood gas values). It was decided to monitor arterial oxygenation as an index of
effect of treatment on the lungs, rather than indirect measurements of delivery of
oxygen to tissues such as mixed venous oxygen saturation or lactate.
71
The reasons are as follows.
Mixed venous saturation is conventionally obtained from the pulmonary artery and
some argue that central venous blood does not correlate well with true mixed venous
samples in any case159. Pulmonary artery catheter placement is associated with
complications (some cite incidences as high as 20%)160. It was felt that correct
placement in vivo of a pulmonary artery catheter in a rabbit would be technically
difficult, a fact subsequently acknowledged 161.
With regard to lactate, although it is used as a means of monitoring adequate
delivery of oxygen to tissues of the whole body, it may take several hours for a
change in lactate levels to develop. The change in lactate levels may occur relatively
1 fx) • • •
slowly and many investigators monitor lactate levels over several hours e.g. 24
hour time periods163'164. Although lactate is a reasonable marker to follow progress
of a disease on the ITU, the duration of the study was to be a maximum of 12 hours
after lung injury. It would also have involved the purchase of a relatively expensive
analyser.
Continuous monitoring of oxygenation was achieved by a pulse oximeter probe
applied to the rabbit's tongue using an Ohmeda Biox 3700 pulse oximeter (Datex-
Ohmeda, Stirling, Scotland). Arterial blood gases were checked on a CIBA Corning
238 blood gas analyser (Chiron Diagnostics, Halstead, Essex, England), calibrated
for PaC>2, PaCC>2 and pH against standard calibration solutions provided by the
company.
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Measurement of total respiratory system dynamic compliance with the Ventrak
1550 respiratory mechanics monitoring system.
Dynamic compliance of the respiratory system (Cdyn) was measured by using a
Ventrak 1550 respiratory mechanics monitoring system (a fixed orifice, differential
pressure flowmeter), with a flow and pressure transducing head fixed to the top of
the endotracheal tube (Novametrix Medical Systems, Wallingford, Conn., USA)165.
The Ventrak is a custom designed flowmeter intended to minimise the effects of
condensation on flowmeter performance. The output pressure versus flow
relationship for the Ventrak head is non-linear. The non linearity of the Ventrak flow
head is corrected in the signal processing.
The linearity of the flowmeter of the Ventrak was tested with 100% oxygen using a
Timeter Calibration Analyser Series RT 200 and an FC014 Micromanometer,
Furness Controls Ltd, Bexhill UK. The results of these assessments are shown in
Table 3 and Figure 4 which appears at first glance alinear.
However the output pressure from the Ventrak flow head is further processed by the
Ventrak system and the integrated volume from the Ventrak was used in
calculations.
To assess the linearity of the combined Ventrak flow and volume measurement
system, the output of the device to a standard volume delivered at different speeds
was assessed, using a four-fold difference in time to deliver a known volume. A
Hans Rudolph 5510 Series Calibration Syringe was set to 40ml and the volume was
delivered through the transducer head. The output signal representing volume from
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the Ventrak was measured by capture into a Cambridge Electronic Design Micro
1401 signal acquisition system (C.E.D., Cambridge, England). The approximate
range of flow rates for rabbit weights 2.3-4.3 kg (thus tidal volumes 23-43ml)
respiratory rates of circa 30/ minute, and inspiratory times of circa 1 second is
approximately 1.3-2.7 litres/minute. Therefore flow rates over this range were used
to assess the linearity of the volume output. The results of this assessment are shown
in Table 4 and Figure 8.
The flow signal appears to have been adequately linearised. Over these flow ranges,
the change in output amounts to 1.5ml for a mean volume of 34.3ml i.e. a variation
of 4.4%. This relationship was considered satisfactory for estimates of Cdyn where
the changes expected were between 10 and 20%, particularly since the flow range
for each animal would be less than this imposed range, and the variation within each
animal would be less.
The dynamic compliance was calculated by dividing the inspired tidal volume
(obtained from the Ventrak) by the difference between the peak inspiratory pressure
(obtained from the Ventrak) and the end-expiratory pressure at points of zero flow
and was corrected for body weight (giving units of ml cm F^O"1 kg"1). The inspired
tidal volume was chosen for standardisation, because if expiratory tidal volume had
been chosen in some groups there would have been the confounding element of
exhaled PF 5080 vapour.
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Table 3a. Linearity of Ventrak (Inspiratory) measurement system











Table 3b. Linearity of Hans-Rudolph Pneumotachograph












The viscosity and density of PFC vapour interferes with flow measurement devices
such as the pneumotachograph and the Ventrak flow head. This is recognised by
other researchers 166. In the group given nebulized PF 5080, administration was
stopped briefly whilst Cdyn was determined.
Baseline recordings of dynamic compliance (Cdyn) were made after adequate lung
injury had been achieved and the randomisation process had taken place (vide infra)
Measurement of total respiratory system static compliance using the Hans
Rudolph 4500B Pneumotachograph..




Schematic Representation of the Hans Rudolph Pneumotachograph.
(A) The occlusion device is inserted into the ventilator circuit. The






(B) The airway is occluded at peak inflation, trapping a breath in the rabbit's














There was a rotatable valve which enabled different channels to be opened or closed.
The resistance of the pneumotachograph and occlusion device combined was
essentially that of the pneumotachograph. With the device inserted into the
respiratory circuit the rabbit could be ventilated normally. The device had a side port
for sampling proximal airway pressure using a Furness Controls differential pressure
transducer (0-10 kPa).
The airway was briefly occluded at end inspiration using a two-way occlusion
device (see Figure 5). Proximal airway pressure was measured. The occlusion device
was then switched allowing the animal to exhale completely to atmospheric pressure
through a Hans Rudolph 4500B pneumotachograph connected to a Validyne MP45
differential pressure transducer (±2 cm H20). Once the breath had been sampled the
occlusion device was switched back, and mechanical ventilation with positive end-
expiratory pressure was resumed. During measurements, airway pressure and
expiratory flow were sampled to an online personal computer at 250 Hz. The airway
pressure was inspected to ensure that a stable plateau pressure (approximately
200ms) had been obtained following the airway occlusion. Crs was calculated as the
volume exhaled to atmospheric pressure divided by the plateau pressure and
corrected to body weight (ml cm H20_1 kg"1). Each Crs value was taken as the
average Crs obtained from at least five different breaths. To obtain an indication of
the consistency of measurement, the coefficient of variation [(the standard deviation
of the value of breaths/ their mean) xlOO] of each average Crs value was calculated.
The distribution of these values is shown in Figure 6.
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The mean coefficient of variation was 2.7% (SD 1.4%) with a minimum of 0.6% and
a maximum of 8.5%. This suggests that the measurements were of an acceptable
consistency. The total number of estimates of coefficient of variation was 147.
As gases of differing viscosity affect the pressure drop across the
pneumotachograph, it was not possible to use the pneumotachograph for the
following treatment groups;
i) Poured PF 5080
ii) Nebulized PF 5080
iii) Pumactant combined with poured PF 5080
iv) Curosurf combined with poured PF 5080.
Thus Crs measurements are considered only from animals that were not treated with
PFC.
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Figure 6. Bar chart showing distribution of Coefficient of Variation obtained
for Crs estimates made with the Hans Rudolph pneumotachograph. This
sample is for all the measurements of Crs noted in all animals (n=147).
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Reproducibility of measurements of static compliance of the respiratory system.
The airway pressure transducer and the pneumotachograph were tested repeatedly
against a known pressure of 20 cm H2O with a water manometer and a known
volume of 50 ml against a Hans Rudolph 5510 Series 50ml calibration syringe, using
100% oxygen before each animal was measured (see Figures 7a and 7b). Pressure
calibration gave a mean pressure of 19.8 cm H2O (SD 0.2 cm H2O; n=26). Volume
calibration gave a mean volume of 50.1ml (SD 0.3ml; n=27).
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Figure 7a Scatter plot showing reproducibility of volume measurements for
Hans Rudolph Pneumotachograph. Volume calibration against a Hans
Rudolph 5510 Series 50ml calibration syringe. Mean volume shown 50.1 ml







Figure 7b. Scatter plot showing reproducibility of pressure measurements for
Hans Rudolph pneumotachograph. Pressure calibration gave a mean
pressure of 19.8 cm H20 with a minimum of 19.5 cm H20 (SD 0.2 cm H20)



















Table 4. Table of assessment of linearity of volume measurements. Ten
measurements at each delivery speed. Values are means (SD).
Duration of Flow in Seconds. Volume Measured in ml.
0.67 (0.06) n=10 33.4 (0.67)
1.2 (0.22) n=10 34.5 (0)
2.39 (0.43) n=10 34.9 (0.55)
Figure 8 Linearity of volume measurement system of Ventrak
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Dynamic Compliance versus Static Compliance
Dynamic compliance is simpler and less time consuming to measure than the static
compliance measurement technique described above. However differences may
occur between values obtained for Crs and Cdyn, due to difference in either tidal
volume or end expiratory pressure 168 131. In this thesis the ventilator settings were
adjusted to generate a tidal volume of lOml/kg by altering peak inspiratory pressure
thereby keeping tidal volume constant. However the technique for measuring Cdyn
above measures the set level of PEEP whereas the technique for measuring Crs
allows the rabbit to exhale to atmospheric pressure. This may allow the rabbit
compliance to be sampled at differing points on the pressure-volume relationship i.e.
to have differing compliances.
Dynamic compliance is frequency dependent and includes resistive and viscoelastic
components in its measurement16<). Therefore it was important for a standardised
respiratory rate to be used in the ventilatory protocol.
Some investigators advocate that the effects of surfactant therapy are best
characterised by changes in maximum compliance measured by static not dynamic
compliance l68.
Mode of inducing lung injury
The mode of inducing lung injury was by repeated warmed 0.9% saline lavage
similar to that described by Lachmann et al133'148. The rabbit has a functional
residual capacity of approximately 20ml/kg149 ,7(). Thus 20ml/kg was repeatedly
introduced to the respiratory tract at 5 minute intervals with a dwell time of 1 minute
in the supine position. The animal was then turned so that the saline reached all areas
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of the lung. In order to generate an adequate tidal volume of gas, during the saline
lavage, peak inspiratory pressure (PIP) was increased to 24cm H2O.
Lung injury was standardised as follows. Oxygenation was monitored with a
peripheral pulse oximeter attached to the tongue, and checked by arterial blood gas
analysis. An adequate amount of lung injury was deemed to have occurred when the
arterial partial pressure of oxygen (PaCh) was less than 13.3 kPa (lOOmmHg)122'134
based on 2 blood gas analyses 15 minutes apart, at a peak inspiratory pressure of 24
cmbhO and 4cm H20 PEEP.
At this point the animal was randomised to one of seven treatment groups, by
random selection of unmarked sealed envelopes.
1) The Control Group (20 animals)
The peak inspiratory pressure was adjusted to generate a tidal volume of lOml/kg
and a respiratory rate of 30 breaths per minute as described below. No further
treatment interventions were given other than the administration of maintenance
fluids. At the end of the experiment, 10 animals had their lungs preserved by
immersion in formalin, and 10 by immersion in liquid nitrogen.
2) The Poured PFC Group i.e. PLY (12 animals).
These animals were given an FRC (20ml/kg) dose of warmed PFC (PF 5080), or
until a meniscus was seen in the endotracheal tube at sternal level with PEEP
temporarily switched off so the level could be checked. Evaporative losses were
replaced throughout the study by infusion of PF 5080 into the side arm of an
endotracheal tube connector such that a meniscus was maintained at this level,
checked intermittently at zero PEEP. If required, further top-up boluses were
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administered to maintain the meniscus. At end of the experiment, 6 sets of lungs
were immersed in formalin, and 6 immersed in liquid nitrogen.
3) The Nebulized PFC Group (10 animals^)
This group were given a similar initial loading ("FRC") dose of 20ml/kg PF 5080, to
that administered in the Poured PFC group, but this dose was administered by an
ultrasonic nebulizer (Devilbiss Ultra-Neb 2000, Sunrise Medical, UK) set at
maximal output (1.63Megahertz). As nebulized PFC had not previously been
administered as a means of treating the injured lung, there was no specific
information available on this technique. The general principles adhered to are shown
below.
An ultrasonic nebulizer was used for the reasons discussed above, and the Devilbiss
Ultra-Neb used was the ultrasonic nebulizer available for the project. The setting
was chosen to be in the range most likely to deliver particles to the alveoli (<5
07 #
microns) as discussed previously.
The size of the particles generated had been bench tested prior to the study in
collaboration with colleagues at the Institute of Occupational Medicine, using a
Hiac/Royco 4100/1200 particle counter171 (Menio Park, California, USA; threshold
0.3 microns) and the SLE 250 ventilator. The nebulization chamber was 30 cm from
the test lung as suggested as the optimal distance for ultrasonic nebulization112, and
the particle counting was performed immediately prior to the test lung. Various
volumes for nebulization ("Charges") were tested. The results from this are shown in
Table 5.
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85 773 56 203 8 366 7 389
microns
0.5-1.5 68 578 22 731 3 584 348
microns
1.5-3.0 51 580 2654 437 6
microns
3-5 2616 18 21 0
microns
5-10 4 0 0 0
microns
>10 microns 0 0 0 0
On the basis of this, nebulization was performed in 10ml aliquots i.e. if a total of
80ml were to be nebulized, it was nebulized as 8 aliquots of lOmls.
The estimated hourly maintenance requirements to replace evaporative PFC losses
were calculated as follows (after the formula suggested by Salman et al)109.
89
Assuming a tidal volume of 1 Oml/kg, hourly ventilation was
Tidal Volume x Resp. Rate x 60 minutes/hour
1 Oml/kg e.g. 30 breaths/min x60
i.e ventilation = 18 000 ml kg^hour"1
Vapour pressure of PF 5080 at 37°C = 6.8 kPa. Thus 6.8 volumes % of ventilation
/hour
Thus 6.8/100 x 18 000 1224 ml kg"1 hour"1
At Standard Temperature and Pressure 1 mol. of gas occupies 22 400ml. Thus
1224ml will contain 1224/22400 ml = 0.05mol
Molecular weight PF 5080 = 438 Daltons
So 0.05mol =21.9g
Thus 21.9g PF 5080 evaporated kg^hr'1
Density of PF 5080= 1.76g/ml
Thus approximately 13ml PF 5080 evaporated kg"'hr"'
Due to the flow bias of the SLE 250 ventilator this does not necessarily imply that all
of this was delivered to the lungs. This point is dealt with later in the discussion
sections.
All the lungs were immersed in liquid nitrogen at the end of the experiment.
4) The Pumactant only Group ( 10 animals)
This group were given lOOmg/kg of the apoprotein free surfactant (Pumactant). This
is the dose of phospholipid most often used in animal studies of exogenous
surfactants 126. Pumactant was injected into the trachea via the endotracheal tube as a
single bolus. PIP was adjusted to generate an inspiratory tidal volume of 1 Oml/kg.
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No other interventions were made. All animals had formalin histology preparation
post mortem.
5) The Curosurf only Group (10 animalsl
This group was given lOOmg/kg of the apoprotein containing surfactant Curosurf,
injected into the trachea via the endotracheal tube as a single bolus. PIP was adjusted
to generate an inspiratory tidal volume of lOml/kg. No other interventions were
made. All these lungs were immersed in formalin at the end of the experiment.
6) Combined treatment with Pumactant/PLV (10 animals')
This group was given lOOmg/kg of the apoprotein free surfactant Pumactant, then
poured PFC as for the PLV group i.e. PF 5080 in an FRC (20ml/kg) dosage of
warmed PFC (PF 5080), or until a meniscus was seen in the endotracheal tube at
sternal level with PEEP temporarily switched off. Evaporative losses were replaced
throughout the study such that a meniscus was maintained at this level, checked
intermittently at zero PEEP. All these lungs were immersed in formalin at the end of
the experiment.
7) Combined treatment with Curosurf/PLV ("10 animals)
This group was given 1 OOmg/kg of the apoprotein containing surfactant Curosurf
lOOmg/kg, then poured PF 5080 as above. All these lungs were immersed in
formalin at the end of the experiment.
After randomisation the animals were returned to ventilation with an inspiratory tidal
volume of lOml/kg (maximum inspiratory pressure 45 cmFLO) for 15 minutes prior
to administering the randomised treatment. Lung mechanics, haemodynamic and gas
exchange parameters were then checked at hourly intervals. The PaCC>2 was kept
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within the approximate normal range (4-6kPa) for the rabbit , by adjusting the
respiratory rate. If a respiratory rate greater than 35 was required then the inspiratory
time was reduced.
Blood gas, Cdyn and where appropriate Crs parameters were measured hourly until
death or until twelve hours after lung injury criteria were achieved. Surviving
animals were killed at this point by an overdose of anaesthetic.
The lungs were then clamped in end-expiration and the lungs removed en-bloc. They
were then either immersed in liquid nitrogen (if randomised to be in the CT scanning
arm of the study as further described in chapter 6 below) or otherwise 10% buffered
formalin.
As additional proof of adequacy of lung injury, at the end of the study, 10 of the
twenty control animals had representative lung samples taken for histological
analysis (7 samples per case). Rabbit 2's lungs had been immersed in liquid nitrogen
first (from the Control CT data group) and after the CT data had been obtained, was
immersed in 10% buffered formalin. All others were directly immersed in 10%
buffered formalin. These samples were prepared by Dr William Wallace, Consultant
Pathologist, Edinburgh University Medical School. The data on these samples are
given in Table 9 (Chapter 3). Photographs of the haematoxylin and eosin stained
microscope slides from some of these samples are shown in Figure 10 in Chapter 3.
Further details with regard to the separate arms of the study are detailed and
emphasised in the individual chapters below.
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Chapter 3
The effect of Partial Liquid Ventilation with PF 5080 on
survival times; a randomised, controlled comparison of PF
5080 alone, and with and without combinations of Curosurf
or Pumactant.
Summary
The aim of this chapter was to investigate any differences in survival to twelve hours
after achieving lung injury, between the seven treatment groups referred to in the
previous chapter.
Results were analysed by comparing Kaplan-Meier survival curves using a Logrank
test.
There was a significant difference between the groups treated with partial liquid
ventilation and the control group, and between the combination of Pumactant and
partial liquid ventilation and control. There was a trend towards an improved




Partial liquid ventilation may improve chances of survival in the context of acute
lung injury. Some previous animal studies of acute lung injury had dealt with very
short term survival (to 3-4 hours)134 and none had used the PFC as the preparation
PF 5080 in a rabbit model of acute lung injury. This study wished to test the effects
of PLV with PF 5080 on survival over a longer period of time (to twelve hours post
lung injury, the maximum period allowed under the Home Office Licence for the
study).
A further hypothesis was to be tested. Surfactant deficiency, and surfactant
inactivation are well recognised features of ARDS 44;49;53;56;57 and may well be
responsible for the early changes of compliance seen during the initial stages of
development of the syndrome. The airway atelectasis and loss of FRC with increase
in right to left shunt leads to the hypoxaemia. Thus modes of therapy which help
maintain an adequate FRC and improve oxygenation may stop the slide towards
continuing hypoxaemia and premature death.
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Methods
A total of 82 young adult female New Zealand white rabbits (weight range 2.31 -4.27
kg; mean weight 3.46 kg; standard deviation ± 0.40kg) were studied during these
investigations. Anaesthesia, preparation and induction of lung injury were as
described in chapter 2. As there were no previous studies on survival to twelve hours
in this experimental model, for these treatment groups, power calculations were
made on the basis of similar though not identical studies, as discussed in chapter 1.
After achieving adequate lung injury (PaC>2 <13.3 kPa) the animals were randomised
to one of seven treatment groups, again as described in chapter 2;
i) Control (20 animals);
ii) Partial liquid ventilation i.e.poured PF 5080 (12 animals);
iii) Nebulized PF 5080 (10 animals);
iv) Pumactant lOOmg/kg body weight (10 animals);
v) Curosurf 1 OOmg/kg body weight (10 animals)
vi) Pumactant then partial liquid ventilation with PF 5080 (10 animals);
vii) Curosurf then partial liquid ventilation with PF 5080 (10 animals).
After randomisation the animals were returned to ventilation with an inspiratory tidal
volume of lOml/kg. After 15minutes lung mechanics, haemodynamic and gas
exchange parameters were rechecked, and repeated at hourly intervals, time zero
being taken as the time that lung injury criteria were achieved. The randomised
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treatment intervention was made and hourly blood gas parameters were checked
thereafter.
The PaC02 was kept within the normal range by adjusting the respiratory rate. If a
respiratory rate greater than 35 was required then the inspiratory time was reduced.
Hypotension thought to be due to hypovolaemia was treated with boluses of fluid, in
addition to the background intravenous fluid infusion (7ml kg"'hour"1).
Those animals still alive 12 hours after achieving lung injury criteria were
euthanased by an overdose of general anaesthetic. The lungs were then clamped in
end-expiration and excised en bloc.
The excised lungs were either prepared for histological examination by liquid
nitrogen or formalin immersion. Histological analysis is included merely to




Kaplan-Meier survival curves 140 are shown for the respective treatment groups
(Figure 9). Comparison between pairs of groups was made using the Logrank test
139'140, on the statistics program of GraphPad Prism™ Version 4.0 (GraphPad
Software Inc., San Diego, California, USA). Analysis of the Logrank test gave the
following results.
All comparisons made with the control group. A P value of <0.008 was taken as
significant (Bonferroni's correction for 6 comparisons i.e. 0.05/6).
Partial liquid ventilation i.e. poured PF 5080 demonstrated a significantly improved
survival compared with control (P = 0.0019)
Pumactant and partial liquid ventilation combined demonstrated a significantly
improved survival compared with control (P = 0.0048)
The other comparisons to control yielded the following P values, all of which were
not statistically significant at P > 0.008;
Nebulized PF 5080 (P = 0.6061)
Pumactant (P = 0.2014)
Curosurf (P = 0.0092)
Curosurf and poured PF 5080 (P = 0.0520)
Survival times and number of animals with evidence of pneumothorax
Table 6. The incidence of pneumothorax between groups compared by




The amount of PF 5080 administered to the respective groups is displayed in Table
7. The nebulized group were given significantly more PF 5080 (although this does
not imply that it all reached the alveoli). Additional fluid requirements for each
group are shown in Table 8. No group was given significantly more fluid than any
other group.
Table 9 describes the histological findings of representative samples from the control
group of animals (in terms of acute interstitial inflammatory infiltrate, hyaline
membranes and histological confirmation of acute lung injury as well as survival
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Table 6; Survival Times and number of animals with pneumothorax present.
Number of Number of Minimum 25% Median 75% Maximum
Animals Animals survival Percentile Survival Percentile Survival
with Time (Minutes) Time (Minutes) Time
Pneumo- (Minutes) (Minutes) (Minutes)
thoraces
Control 20 4 23 172.5 297 565.5 720
Poured 12 4 380 598.5 669 720 720
Neb. PFC 10 2 73 134 363 611.5 720
Pumaetant 10 0 192 306.5 379 588.5 720
Curosurf 10 5 306 571.5 626.5 720 720
Pum/Pour 10 4 66 532.5 720 720 720
Curo/Pour 10 6 161 445.5 557.5 671 720
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Table 7
Amount of PF 5080 administered per minute of survival. Data are means
(with standard deviations).
Group Amount of PF 5080 administered
(ml/min)
Partial Liquid Ventilation 0.67 (0.12)
(n=12)
Nebulized PFC 0.89 (0.20)
(n=10)
Curosurf + PLV 0.72 (0.16)
(n=10)
Pumactant + PLV 0.70 (0.14)
(n=10)
Comparison between groups by ANOVA with Newman-Keuls post hoc test.
Statistically significant differences between;
Nebulized and PLV (PO.Ol)
Nebulized and Curosurf/PLV combination (P<0.05)
Nebulized and Pumactant/PLV combination (P<0.05)
All other comparisons were not statistically significant.
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0.0 10.0 49.0 96.0 300.0
Pour(n=12) 20.0 60.0 102.5 130.0 170.0
Neb. PFC
(n=10)
0.0 45.0 60.0 70.0 180.0
Pumactant
(N=10)
0.0 35.0 100.0 135.0 240.0
Curosurf
(n=10)
0.0 0.0 30.0 73.0 150.0
Pum/Pour
(n=10)
0.0 60.0 105.0 120.0 135.0
Curo/Pour
(ii=10)
40.0 92.5 115.0 180.0 210.0
Groups compared by non-parametric Kruskal-Wallis test with Dunn's post test (as
values do not correspond to a normal distribution). No significant difference
between any group (P > 0.05).
Histology
Ten samples were taken from the lungs of control rabbits to assess the degree of lung
injury. The pathologist reported that 9 of 10 rabbits showed "unequivocal evidence
of acute lung injury with variable interstitial and airspace infiltration by neutrophils
and hyaline membrane formation". The 10th case (the first rabbit in the study) was
more equivocal but showed at least "mild focal infiltrates". A summary of the
pathologist's findings is shown in Table 9, and pictures of representative
haematoxylin and eosin microscope slides are shown in Figure 10. Inflammatory
cells, haemorrhage, hyaline membrane formation and destruction of lung architecture
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including necrosis are shown on the photographs, all features consistent with acute
lung injury 157.
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Rabbit 55 Mild diffuse Diffuse Yes 683





Rabbit 68 Mild diffuse Focal Yes 202
Rabbit 70 Mild diffuse Focal Yes 314
• Rabbit 59 In comment section. "Focal injury very severe with possible early
necrosis".
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• Key to arrows on photographs of histology slides (Figure 10).
A = Necrosis
B = Intraluminal neutrophils
C = Interstitial neutrophils
D = Hyaline membrane
E = Red blood cells
The first picture showing necrosis is taken from Rabbit 59. The other examples






The relative merits of the various common means of inducing experimental lung
injury, and the reasons why the saline lavage method was chosen for this study were
discussed in chapter 2.
The lung injury caused by saline lavage in this study was graded from mild to severe
(widespread hyaline membranes, inflammatory infiltrates and foci of necrosis).
However in some animals the acute interstitial inflammatory infiltrate was graded as
either mild or mild to moderate. In part the limited inflammatory infiltratration may
be caused by the limited time from injury to death.
Five of the ten animals showed diffuse hyaline membrane formation with a further
four showing focal hyaline membranes.
In nine of the ten control animals, acute lung injury was confirmed to be present on
histological examination. All animals from all groups had to have an arterial PaC>2
less than 13.3 kPa with an F1O2 of 1.0, to confirm an adequate and standardised
hypoxaemia had been caused by the saline lavage process. It is possible that some of
these animals had a not particularly severe insult on histological evidence. However
all were lavaged to a similar severity of hypoxaemia, and were then randomised.
Thus there should have been an equal distribution of less severely injured animals
across treatment groups.
This is the first study of partial liquid ventilation (PLV) with PF 5080 to determine
the effect on survival in a rabbit model of ARDS. Other studies have considered
fewer animals and generally over a shorter period of study ,22'134. It was found that
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PLV and the combination of pumactant and PLV prolonged survival in comparison
to controls. With regard to the number of animals in each group, and the multiple
comparisons which were made, the study had sufficient power to detect substantial
differences only. Although none of the other treatments were associated with a
significant prolongation of survival, inspection of the Kaplan-Meier survival curves
suggests that some of the other treatments, particularly Curosurf or the combination
of Curosurf and PLV, may have prolonged survival. A type II error cannot be
excluded. For example, assuming a type I error of 0.05 and assuming a power of the
test of 0.8 in order to detect a difference between control (median survival 297
minutes) and Curosurf (median survival 626.5 minutes), there would have to have
been 32 animals in the Curosurf group (PS Power and Sample Size Calculations
;Copyright 1997 by W.D. Dupont and W.D. Plummer l42). These median survival
values were only available at the end of the study, and had not previously been
published, as mentioned in chapter 1. Trying to discern differences between other
groups where there appears to be less of a difference in effect on inspection of the
Kaplan-Meier survival curves would have required vast numbers of subjects outwith
the scope of this project. Again for example, to determine a difference between
control and Pumactant assuming the type I + II errors above would require 257
animals per group.
Possible causes of death in these animal studies of ARDS have been cited as
pneumothorax and intractable hypoxaemia134.
The number of animals who developed a pneumothorax is shown in Table 6. The
• • • • • • 2differences in proportions between the groups were not statistically significant (x
Test). Pneumothoraces were frequently observed in all study groups except those
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animals treated with Pumactant alone. However, the median (interquartile range)
time post randomisation to diagnosis of pneumothorax was 564 (356-628) minutes,
by which time 7 of the 10 rabbits in the Pumactant only group had died.
Pneumothoraces may not always be diagnosed close to their time of onset. Some of
the pneumothoraces were only diagnosed post-mortem when the abdomen was
incised and the diaphragms inspected at autopsy. Furthermore, the study protocol did
not allow for the treatment of any pneumothorax diagnosed ante-mortem by what
would be the normal clinical practice of inserting an intercostal drain. Some authors
have suggested that in animals treated with PLV pneumothoraces do not become
apparent until PFC starts to evaporate off. Prior to this, the lung can be splinted by
the volume of liquid it contains 80. The non-dependent lung may particularly be
prone to overdistention during partial liquid ventilation '.
Administration of nebulized PFC as a means of supporting the injured lung had not
been described previously. There was no meniscus to ascertain degree of filling of
the lung with PFC. The amount of PFC administered per minute of survival post
randomisation is noted in table 7.
The amount of nebulized PF 5080 actually deposited in the lungs would have been
difficult to ascertain in vivo. Bench testing prior to performing these studies (see
Table 5) suggested that the optimal setting for the ultrasound nebulization of PF
5080 to deliver to the end of the inspiratory limb of the ventilator was at "maximal"
on this make of nebulizer. This is approximately a frequency of oscillation of 1.63
Megahertz. Indirect evidence that the PFC was being delivered to the endotracheal
tube was the immediate change in the inspiratory volume shown by the Ventrak
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analyser sited directly proximal to the endotracheal tube. This implied the presence
of an additional substance. From table 7 the nebulized PF 5080 group appear to have
been given a greater amount of PFC. However this does not imply that the substance
was delivered to the lower parts of the respiratory tract. One conclusion for the
failure of nebulized PF 5080 to affect survival is that no significant amounts of
nebulized PFC actually reached the lungs.
One other interpretation is that if given by a nebulized route the PF 5080 would only
reach the well ventilated (i.e. less severely affected) parts of the lungs and little
reached the atelectatic parts of the lung most in need of treatment.
Surfactant had no effect on survival in this study. The study protocol allowed for
only 1 dose of surfactant, where the PF 5080 groups were treated continuously with
PFC. There may have been a greater effect on survival if re-dosing of surfactant had
been allowed. Alternatively, there may have been a type II error, which would not
have been present if resources had allowed a larger study as noted above. The
difficulty in making power calculations for survival for this specific group, where no
direct previous references were available, was discussed in chapter one.
Preparations of surfactant which do not contain apoproteins such as Pumactant
appear to be inferior to those which do in the presence of acute lung injury132 129.
Apoprotein free preparations are more susceptible to inactivation by inhibitory
proteins.
The failure of the combination of Curosurf with partial liquid ventilation to have any
additional survival advantage over control or indeed over the individual therapies
alone could be explained as follows. Natural surfactants have the ability to reduce
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surface tension to near normal values. PF 5080 has a fixed surface tension
(15dyne/cm from 3M data sheet). Thus coating the lungs with an agent with a poorer
surface tension reducing properties (replacing Curosurf with PF 5080) may lead to a
poorer outcome. The inhomogenous nature of ARDS may means that there were
some areas of lung able to achieve very nearly a normal surface tension (Curosurf
coated) and areas with a substantially higher surface tension (PF 5080 coated)
generating shearing forces 15 48 and consequent adverse events.
The rapid action of apoprotein containing surfactant173 may have restored FRC to
near normal 168. Partial liquid ventilation with relatively large tidal volumes at near
FRC may be dangerous. Cox and colleagues found that 10 from 13 of their saline
lavaged rabbits ventilated with tidal volumes of 15ml/kg on top of 18ml/kg of
Perflubron, developed pneumothoraces within 2 hours.8 Tutuncu would argue that
• 158
a ceiling effect is seen in terms of improving compliance with only 3ml/kg . To
minimise lung overdistention some authors have recommended that PLV be used
only with a pressure controlled mode of ventilation.66
One interpretation of the improved survival of the combination of Pumactant/PFC is
that the Pumactant contributed little in the way of activity as it was inactivated by
inflammatory mediators within the alveoli. There was no marked contrast in surface
tension between (Pumactant) surfactant coated areas and PFC coated areas as there
could be in the Curosurf/PFC group and thus less shearing forces. Hence the
improved survival of the combination of Pumactant/PFC was essentially that
contributed by the PFC.
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In summary partial liquid ventilation with either PF 5080, or the combination of
Pumactant and partial liquid ventilation with PF 5080 improves survival to 12 hours
in rabbits after saline lavage lung injury.
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Chapter 4
The effect of Partial Liquid Ventilation (PLV) with PF 5080,
nebulized PF 5080, surfactant preparations and
combinations of PLV with surfactants on arterial
oxygenation.
Summary
The aim of this chapter was to investigate any differences in oxygenation between
the seven treatment groups.
The effect of PLV with PF 5080 alone on arterial oxygenation was compared with
combinations of surfactants given alone or in combination with PF 5080, as well as
with nebulized PF 5080, on the population of 82 lung injured female New Zealand
white rabbits described in chapters 2 and 3. After inducing lung injury by repeated
saline lavage, the animals were randomized to the seven groups described in chapter
2
Arterial oxygenation was measured immediately prior to treatment and at 1, 3 and 6
hours after achieving adequate lung injury. Statistical analysis compared to control
was done at each time point by ANOVA with Newman-Keuls test for multiple
comparisons.
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Oxygenation was improved in the animals treated with PLV, Curosurf and the
combinations of Pumactant/PLV and Curosurf/PLV at 1, 3 and 6 hours. There
no difference in the oxygenation between these four groups.
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Introduction
One of the defining features of ARDS is a severe hypoxaemia.8 Hence a question for
any method of supporting the injured lung is, can the patient or subject be
oxygenated adequately? PF 5080 had never been used for this purpose in a rabbit
model of acute lung injury. Additionally, could nebulization of PF 5080 lead to a
better oxygenation than pouring the PF-5080 into the respiratory tract?
Although surfactants had been used in animal models of ARDS they had been used
with variable success 129;132;1S ;151;174, and no direct comparison had previously been
made between the effects of Pumactant and Curosurf on oxygenation in an animal
model of ARDS.
Lastly would an additional effect on oxygenation be seen by combining the varying
surfactant preparations with PF 5080 during PLV?
This part of the project was designed to answer these questions.
Methods
The animals were anaesthetised and prepared, and lung injury was induced as
described in chapters 2 and 3. When adequate lung injury had been achieved (PaC>2 <
13.3kPa) the animals were randomised to the groups described previously. After
randomisation ventilator settings returned the tidal volume to lOml/kg and 15
minutes later baseline arterial blood gas measurements were made immediately prior
to the treatment, and at time points 1, 3 and 6 hours after achieving adequate lung
injury. Measurement were made to 6 hours only as there were too few survivors in
some groups (control, nebulized PF 5080 and Pumactant groups) beyond this time
for further valid comparisons to be made.
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Statistical analysis was performed with Analysis ofVariance (ANOVA), having
checked that the values corresponded to a normal distribution using the
Kolmogorov-Smimov test. The statistical package used for this was GraphPad
Prism™ Version 2.0 (GraphPad Software Inc., San Diego, California, USA).
118
Results
Results are shown below.
Table 10 shows Pa02 values for the seven treatment groups, and shows no difference
between groups prior to injuring the lungs.
Table 11 shows the PaC>2 for each treatment group after lung injury (but before
treatment was given) and at the 1, 3 and 6 Hour time points. There was no difference
between the groups immediately after lung lavage.
The results show a highly statistically significant improvement in oxygenation
compared to control for the PLV, Curosurf and combination groups at 1 and 3 hours
(PO.OOl), and for the Pumactant/PLV combination at 6 hours (PO.OOl). There was
also a statistically significant improvement in the poured PF 5080, Curosurf and
combined Curosurf/ PF 5080 at 6 hours (P<0.01). There was no statistically
significant difference between PLV, Curosurf or either of the combination groups
when compared to each other.
The groups treated with Pumactant or nebulized PF 5080 showed no difference
compared to control. There was no difference between Pumactant and nebulized PF
5080 when compared to each other.
Figure 11 shows a scatter diagram of theses values.
119
Table 10. Pa02 Values Pre-lung injury.
Treatment Group Pa02 kPa mean ± standard deviation
Control n=20 73.45 ± 12.55
Pour n=12 72.96 ±6.46
Nebulized n=10 74.55 ±5.81
Pumactant n=10 75.95 ±5.77
Curosurf n=10 74.49 ± 4.86
Pumactant/PLV n=10 77.42 ± 5.45
Curosurf/PLV n=10 73.99 ±4.18
Values normally distributed (Kolmogorov-Smirnov test). ANOVA shows no
significant difference in Pa02 prior to inducing lung injury.
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Table 11. Pa02 values after lung injury.
Values shown are means ± standard deviation (kPa)
Time 0 Post 1 Hour 3 Hours 6 Hours
Lavage (i.e. Pre
Rx)
Control 6.58 ± 1.70 8.71 ±9.36 6.76 ± 2.00 8.6 ±3.12
Initial n-20 (n= 19) (n= 14) (n=7)
PLV 6.44 ± 1.48 49.03** 39 7** 39.93*
Initial n=12 ± 15.36 ±21.10 ± 22.59
(n= 12) (n= 12) (n= 12)
Nebulized PFC 10.3 ±7.24 6.62 ± 0.89 7.22 ±3.24 6.64 ± 1.28
Initial n=10 II o (n=6) (n=5)
Pumactant 6.86 ± 1.78 7.65 ± 3.60 8.77 ± 8.41 11.80 ±9.99
Initial n=10 (n= 10) (n= 10) (n=6)
Curosurf 7.11 ± 1.06 51.62 ** 43.25** 42.72*
Initial n=10 ±9.83 ± 19.89 ±25.76
(n= 10) (n= 10) (n=9)
Pumactant & 7.56 ± 2.62 48.53 ** 46.50** 52.80 **
PLV Initial ± 10.61 ± 19.61 ± 14.49
n=10 (n=10) (n=8) (n=8)
Curosurf & 6.96 ± 1.68 46.86 ** 49.23** 47.18 *
PLV ± 11.04 ± 15.07 ± 18.62
Initial n=10 (n= 10) (n= 9) (n= 8)
Compared with control group at each time point. Statistical test was ANOVA with
Newman-Keuls test for multiple comparisons. * denotes P<0.01.
** denotes PO.OOl.
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The treatments can be broadly split into two categories ; those which demonstrated a
difference compared to controls (PLV with PF 5080, Curosurf alone and the
combination groups) and those which did not (nebulized PF 5080 and Pumactant
alone).
A common factor in the successful treatments is that they are all means of increasing
the functional residual capacity, or rather preventing end-expiratory collapse 42.
There were no statistical differences between the four effective treatments when
compared to each other. A larger study may have discerned smaller differences.
There are several possible explanations for the failure ofnebulized PF 5080 to have
an effect. First, it is uncertain how much PFC was actually delivered to the lungs. As
shown in the previous chapter, although the mean amount of PF 5080 per minute of
survival placed in the nebulization chamber was greater than the amount poured into
the lungs in the poured or combination groups, the continuous flow bias in the
ventilator circuit (10 1/minute) was approximately 10 times the animals' minute
ventilation. This means that no more than 10% of the PFC would actually have
entered the animals' respiratory tracts. It is unclear how much would actually be
delivered to alveolar level. Also presumably the nebulized PFC would reach only
well ventilated (i.e. non-atelectatic lung regions) where it is not required and little if
any would reach collapsed alveoli. During PLV, the lungs can be filled to a greater
extent, approximating a full liquid FRC.
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On bench testing prior to commencement of this study the ultrasonic nebulizer was
found to generate 50% of the particles less than 1 micron in diameter (see Table 5, in
Chapter 2). This is essentially vaporization. The lack of effect of this route on
oxygenation differs from that found by Bleyl et al155 who found that administering
the PFC perfluorohexane to oleic acid injured sheep improved oxygenation and
pressure volume characteristics sustained over a two hour period. It is hard to
account for these differences, though they were different species and models of lung
injury. They used a circle system of administration rather than a continuous bias
flow ventilator and claim that 20% of their vaporised PFC was retained in the lungs.
It is also possible that perfluorohexane is not biologically inert and in some way
altered pulmonary haemodynamics.
Pumactant the apoprotein free surfactant had no effect on oxygenation. This may be
due to the apoprotein free surfactants being particularly susceptible to inhibition by
protein present in alveoli in acute lung injury 175 176.
In summary, partial liquid ventilation with PF 5080, Curosurf alone and the
combination therapies of Pumactant/partial liquid ventilation with PF 5080 and
Curosurf/ partial liquid ventilation with PF 5080, were all associated with a prompt
and sustained improvement in oxygenation over 6 hours in this model. There were
no statistically significant differences between these groups. In order to discern any
differences larger number of animals would have to have been used.
The administration of pumactant alone or nebulized PF 5080 had no significantly
different effect on oxygenation compared with control animals.
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Chapter 5
The effect of Partial Liquid Ventilation with PF 5080,
nebulized PF 5080, Pumactant, Curosurf and combinations
of surfactants and Partial Liquid Ventilation with PF 5080, on
dynamic and static lung compliances.
Summary
The aim of this chapter was to investigate the effects on lung compliance between
the treatment groups.
The effect on dynamic lung compliance (Cdyn) of PLV with PF 5080, nebulized PF
5080, the surfactant preparations Pumactant and Curosurf individually and
combinations of surfactant and poured PF 5080 was studied in the population of 82
lung injured female New Zealand white rabbits described in chapters 3 and 4, one
three and six hours after achieving adequate lung injury. Additionally, the effect on
static lung compliance (Crs) was studied for control animals and those treated with
the surfactants Pumactant alone and Curosurf alone at timepoints 1, 3 and 6 hours
after achieving lung injury.
Dynamic compliance improved after PLV, Curosurf and the combination of
Curosurf/PLV, although there was no difference between groups and control by 6
hours.
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Static compliance improved after Curosurf though not after Pumactant. This effect
was sustained to six hours.
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Introduction
Impaired surfactant function is a feature of ARDS 50 45 58 Exogenous surfactant
administration may have a role in correcting this deficit 177 54 63. The efficacy of the
surfactant treatment may depend upon the preparation used 1. There had never
previously been a comparison of Curosurf with Pumactant in a model of lung injury.
Partial liquid ventilation has also been used to improve lung mechanics in the
presence of lung injury 91;99;100 but the mode of action may differ from surfactant
administration. There may be some rationale in the co-administration of these agents
to see if there is an additive effect.
Lastly lung compliance may be measured as dynamic or static compliance, as
described in chapter 2. The less cumbersome dynamic compliance technique may
generate results differing from the static compliance technique 131;168 Consequently
where possible both methods were assessed.
Methods
The 82 animals described in the previous chapter were anaesthetised and prepared,
and lung injury was induced as above. When adequate lung injury had been achieved
(PaC>2 < 13.3kPa) the animals were randomised to the groups described in chapters 3
and 4.
After randomisation the pressure level of the ventilator was adjusted back to
generate tidal volumes of lOml/kg. After a further 15 minutes, baseline
measurements of dynamic lung compliance (Cdyn) were made immediately prior to
the treatment and at time points 1, 3 and 6 hours after achieving adequate lung
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injury. These measurements were made in all groups using a Ventrak 1550
respiratory mechanics monitoring system (Novametrix Medical Systems,
Wallingford Connecticut, USA) with a neonatal flow sensor. Cdyn was calculated as
the tidal volume divided by the difference between the peak inspiratory pressure and
the end-expiratory pressure at points of zero flow and corrected to body weight (ml
cmlUCr'kg"1). For the nebulized PF 5080 group the nebulizer was switched off
temporarily so that readings could be made. It was found that the Ventrak recorded
falsely high tidal volumes if readings were made while the nebulizer was running.
Static lung compliance (Crs) measurements were made for control, Curosurf alone
and Pumactant alone groups only by using the modified single breath test as
described in chapter 2. Due to the PF 5080 in exhaled gas it was not possible to use
this technique to measure any animal treated with PF 5080.
Measurement were made to 6 hours only as there were too few survivors in some
groups (control, nebulized PF 5080 and Pumactant groups) beyond this time for
further valid comparisons to be made.
Results are shown below. The statistical package used for this was GraphPad
Prism™ Version 4.0 (GraphPad Software Inc., San Diego, California, USA).
Statistical analysis for the Cdyn and Crs data was performed with Analysis of
Variance (ANOVA) at each time point, having checked that the values corresponded
to a normal distribution using the Kolmogorov-Smimov test.
The Kruskal-Wallis test with Dunn's multiple comparison test was performed on the
respiratory rate data of each group at the time points pre-lavage, post lavage, at 1
hour, at 3 hour and at 6 hours.
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Results
Results are given below.
Table 12 shows baseline dynamic (Cdyn) and static compliance of the respiratory
system (Crs) pre-injury. Data followed a normal distribution for C Dyn. ANOVA
with Newman-Keuls post test shows no significant difference between groups.
Similarly, data followed a normal distribution for Crs. ANOVA with Newman-Keuls
post test shows no significant difference between groups. Thus there was no intrinsic
difference between groups prior to inducing lung injury.
Table 13 shows Cdyn from randomisation (i.e. post injury but pre-treatment) and at
the 1,3 and 6 hour timepoints. There was no difference between groups after lung
injury but before treatment. PLV, Curosurf and the combination Curosurf/ PLV
improved Cdyn compared to control at the timepoint 1 hour (P<0.001). The same
three groups showed a significant effect compared to control at the 3 hour timepoint
(PO.Ol for PLV and and the combination Curosurf/ PLV; P<0.05 for the Curosurf
alone group). By 6 hours, no statistically significant effect could be demonstrated by
any treatment over control.
Table 14 shows the Crs immediately pre-treatment and at time points 1, 3 and 6
hours for the groups Control, Pumactant and Curosurf. There was no difference
between groups after lung injury but before treatment. Curosurf showed a significant
improvement compared to either control or Pumacatant at the 1,3 and 6 hour
timepoints (PO.OOl). By contrast Pumacatant was not statistically different than
control at any timepoint.
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Table 15a-15e shows respectively the respiratory rates before lung injury, after lung
injury and at the 1, 3 and 6 hour time points for all groups.
Figure 12 shows Crs from randomisation (pre-treatment but after injury) to 6 hours
after injury for the groups Control, Pumactant and Curosurf.
Figure 13 shows a scatter diagram of the respiratory rates after injury and at the 1, 3
and 6 hour time points.
Figures 14 (a)-Figure 14 (n) show examples of flow, pressure and volume traces
measured by the Ventrak. These are at the timepoints "baseline" (post injury) and "1
hour" after treatment for sample animals from the respective 7 treatment groups.
Figures 15 (a) - Figures 15 (f) show the flow-volume curves (post lung injury and 1
hour after treatment) for a sample animal in the Control, Pumactant and Curosurf
groups.
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Table 12. Baseline dynamic (C Dyn) and static compliance of the respiratory

















C Dyn 0.89 0.92 0.81 0.85 0.81 0.75 0.88
ml/



















Cdyn and Crs data followed a normal distribution.
ANOVA with Newman-Keuls post test for both Cdyn and Crs data showed no
significant difference between groups.
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Table 13. Dynamic compliance (ml cmH20'1kg'1) from randomisation to 6
hours post-treatment. Data are means (Standard Deviations in brackets)
Number of rabbits at each respective time point denoted by n= number
Group Pre treatment 1 Hour 3 Hours 6 Hours
Control 0.47 0.45 0.39 0.37
Initial n= 20 (0.04) (0.06) (0.07) (0.06)
(n= 19) 3" II ■P* (n=7)
PLV 0.46 0.55*** (0.06) 0.49** 0.45
Initial n= 12 (0.05) (n= 12) (0.07) (0.11)
(n=12) (n= 12)
Nebulized PFC 0.45 0.46 0.41 0.39
Initial n= 10 (0.03) (0.07) (0.05) (0.03)
(n= 10) (n= 10) (n= 5)
Pumactant 0.46 0.44 0.39 0.36
Initial n= 10 (0.05) (0.05) (0.05) (0.06)
(n= 10) (n= 9) (n= 6)
Curosurf 0.47 0.56*** (0.06) 0.47* 0.45
Initial n= 10 (0.02) (n= 10) (0.04) (0.03)
(n= 10) (n= 9)
Pumactant + PLV 0.44 0.50 0.46 0.52
Initial n= 10 (0.06) (0.09) (0.08) (0.19)
(n= 10) (n= 7) (n- 8)
Curosurf + PLV 0.47 0.58*** (0.06) 0.50** 0.52
Initial n-10 (0.04) (n=10) (0.07) (0.07)
(n= 9) (n=8)
Regarding Table 13,Compared with control group at each time point. Statistical test
was ANOVA with Newman-Keuls test for multiple comparisons.
*Denotes P<0.05 . **Denotes PO.Ol
***Denotes PO.OOl
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Table 14. Static lung compliance group means with standard deviations in
brackets. Values are ml cmH20'1 kg'1. n= number of rabbits measured at
each respective time point.
Time 0
(After injury)
1 Hour 3 Hour 6 Hour
Control
(Initial n= 20)






















Groups compared by ANOVA with Newman-Keuls post test for multiple
comparisons. At time zero, no difference between groups.
Curosurf versus Pumactant P<0.001 at time 1,3 and 6 hours
Curosurf versus Control; PO.OOl at time 1,3 and 6 hours.
Pumactant versus Control; no statistical difference at any time point (P>0.05).
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Table 15(a). Respiratory Rate; Pre-lavage.






20 12 10 10 10 10 10
Minimum 21 29 20 20 20 20 28
25%
Percentile
30 30 30 30 30 30 30
Median 30 30 30 30 30 30 30
75%
Percentile
30 30 30 30 30 30 30
Maximum 30 30 30 40 30 30 30
Kruskal-Wallis Test with Dunn's multiple comparison test shows no significant
difference in respiratory rate between any treatment group pre-lavage.
Table 15(b) Respiratory Rate; Post lavage.






20 12 10 10 10 10 10
Minimum 20 25 30 25 30 30 30
25%
Percentile
30 30 30 30 30 30 30
Median 30 30 30 30 30 30 30
75%
Percentile
30 30 30 30 30 30 30
Maximum 35 30 30 37 30 30 30
Kruskal-Wallis Test with Dunn's multiple comparison test shows no significant
difference in respiratory rate between any treatment group post lavage.
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Table 15(c). Respiratory Rate; 1 Hour.






19 12 10 10 10 10 10
Minimum 20 25 30 25 30 30 25
25%
Percentile
30 30 30 30 30 30 30
Median 30 30 30 30 30 30 30
75%
Percentile
30 30 30 30 30 30 30
Maximum 40 35 30 35 31 30 30
Kruskal-Wallis Test with Dunn's multiple comparison test shows no significant
difference in respiratory rate between any treatment group at 1 hour.
Table 15 (d). Respiratory Rate at 3 Hours






14 12 6 10 10 8 9
Minimum 25 22 27 22 25 15 20
25%
Percentile
30 29 20 29 28 22 30
Median 30 30 30 30 30 26 30
75%
Percentile
30 30 30 30 30 30 30
Maximum 30 32 35 35 30 30 30
Kruskal-Wallis Test with Dunn's multiple comparison test shows no significant
difference in respiratory rate between any treatment group at 3 Hours.
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Table 15(e). Respiratory Rate at 6 Hours.






7 12 5 6 9 8 8





28 27 22 28





30 30 30 30
Maximum 1 A n oJO
^ r-
j j 30 35 30 31
Kruskal-Wallis Test with Dunn's multiple comparison test shows no
significant difference in respiratory rate between any treatment group at 6
Hours.
136
Figure 12: Static compliance (ml/cmH20/kg) from randomisation to 6 hours
post-treatment. Data are means (standard deviations)
Crs
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The following pages show traces taken from the Ventrak monitoring system (Figure
14(a) - 14(n). The upper trace is the the flow trace, the middle the pressure and the
lower trace represents volume. Inspiratory flow is shown above the x axis, and
expiratory flow below. Regarding the pressure and volume traces, in each case an
upward deflection represents inspiration and downward deflection expiration. Note
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Comments:
Figure 14(b) Rabbit 15 (Control Group) 1 hour after achieving lung injury.
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Figure 14(d) Rabbit 10 (PLV Group) 1 Hour timepoint.
The expired volume is artefactually greater because of the influence of PF 5080
vapour on the pneumotachograph measurement.
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Date: 11/5/1998 Weight(kg):

























































































Figure 14(f) Rabbit 49 (Nebulized Group) 1 hour. The absence of the overshoot in
the expiratory volume present in all other groups treated with PFC is because the
nebulization was stopped transiently to allow the measurement to be performed.
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Figure 14(g) Rabbit 35 (Pumactant Group) Post Lung Injury.
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Figure 14(i) Rabbit 20 (Curosurf Group) Post Lung Injury.
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Comments:
Figure 14(j) Rabbit 20 (Curosurf Group) 1 Hour.
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Comments:
Figure 14(k) Rabbit 39 (Pumactant/PLV Group) Post Lung Injury.
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Figure 14(1) Rabbit 39 (Pumactant/PLV Group) 1 Hour.
Once again note the effect ofPFC in the exhaled gas.
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Date: 9/8/1998 Weight(kg):
Waveforms starting at: 9/8/1998 12:21:17.00 PM
Comments:
Figure 14(m) Rabbit 37 (Curosurf/ PLY Group) Post Lung Injury
152
Figure 14(n) Rabbit 37 (Curosurf/ PLV Group) 1 Hour
Similar to Rabbits 10 & 39, note the presence of PFC in the exhaled gases.
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The following pages show Flow/ Volume curves for Crs measurements from sample
animals in the Control, Pumactant and Curosurf Groups (Figure 15 (a)- Figure
15(f)). For each animal two curves are shown; the upper curve is post lung injury,
the lower is 1 Hour after the treatment intervention. It is to be stressed that the value
obtained for the exhaled volume is the directly measured volume (not the value
extrapolated from the straight line). The airway pressure was measured with a
differential pressure transducer as described in Chapter 2.
Figure 15(a) Rabbit 74 (Control Group) Post Lung Injury and Figure 15(b) Same
animal 1 Hour later.
Figure 15(c) Rabbit 38 (Pumactant Group) Post Lung Injury and Figure 15 (d)
Rabbit 38 1 hour after Pumactant administration.
Figure 15 (e) Rabbit 73 (Curosurf Group) Post Lung Injury and figure 15 (f) Rabbit
73 1 hour after Curosurf administration.
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VOLUME (11L)
Do you want -to print F-V curve?
Enter LV or N 3:















Do you want to print F-V curve?
Enter t V or N 3:






Do you want to print F—V curve?
Enter t V or N 3
Figure 15 C. Rabbit 38 pumactant group post lung injury
Name - r38-ihr,
Date: 9—9—98
























Do you want to print F—V curve?
Enter tV or N 3:
Figure 15 D. Rabbit 38 pumactant group 1 hour after pumactant administration
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VOLUME (nL)
Do you want -to print F-V curve?
EiTter L V or N ] :
Figure 15 E. Rabbit 73 curosurf group post lung injury
Do you want +o print F—V curve?
Eirter l V or N ] :
Figure 15 F. Rabbit 73 curosurf group 1 hour after curosurf administration
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Discussion.
There was no difference between respective groups for Cdyn or Crs immediately
after achieving adequate lung injury. There was also no significant difference
between the respiratory rates of the treatment groups either immediately after lung
injury or at the 1, 3 or 6 hour time points. If respiratory rates had been markedly
different, this could confound any specific change in Cdyn. In many circumstances
particularly in disease, dynamic compliance is frequency dependent169. A change in
respiratory frequency could affect measurements of Cdyn. However after lung injury
the respiratory rates of the different treatment groups were similar. It is unlikely that
any change in respiratory rate could have concealed any systematic change in Cdyn.
One and three hours after treatment animals who had received PLV with PF 5080,
Curosurf alone or the combination of Curosurf/ PLV with PF 5080 had a
significantly greater Cdyn than control animals. None of these three treatments were
superior to the others. The combination of Pumactant/PLV improved Cdyn at 1, 3
and 6 hours compared to controls, but failed to reach statistical significance at all
three timepoints. Cdyn 1, 3 and 6 hours after treatment in animals treated with
Pumactant alone or nebulized PF 5080 was not statistically different from controls.
After 6 hours Cdyn was similar in all groups. Evolving occult pneumothoraces may
have cancelled out the improvement in Cdyn caused by the treatment intervention.
Of course Curosurf was given as a once only dose. It is possible that Curosurf s
initial effect on Cdyn would have been maintained had repeat doses been
administered. This is supported by Mrozek and colleagues study in saline lavaged
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pigs 145. They found that the transient initial improvement in compliance and
oxygenation diminished over two hours after treatment with the protein containing
surfactant, Survanta.
Static compliance values in animals treated with Curosurf were significantly greater
than controls and Pumactant treated animals at all time points. This is in keeping
with other findings comparing surfactants in animals and human infants129. The
sustained improvement over a six hour period in Crs between Pumactant and
Curosurf, which is not noticed in the 6 hour Cdyn figures may be due to the differing
measurement techniques as discussed in chapter 2 168131. Although there was a
sustained greater Crs with the Curosurf treatment, there was no difference with the
Cdyn measurements. This may be because Cdyn measures different components of
lung mechanics. Cdyn includes resistive and viscoelastic components, and these may
have masked the changes in elastic properties shown by the measurement of Crs 169.
Another technical point to consider is that the respective measuring techniques used
in this project meant that Cdyn was measured with PEEP still applied, where the
technique for measuring Crs allowed the animal to breathe out to atmospheric
pressure. Consequently measurements were made at differing parts of the pressure-
volume relationship of the respiratory system. It is likely that compliance measured
from FRC would be different from that measured at 4cm H2O PEEP. It is possible
that measurements starting from FRC were below an inflection point of the pressure
volume curve and consequently the compliance would be less. However despite this
possibility Crs measurements generally approximated Cdyn measurements. In the
case of the Curosurf group Crs values were generally greater than Cdyn
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measurements. This is because dynamic factors such as airway resistance and
viscoelastic properties affect the Cdyn 169.
The Pumactant preparation had to be reconstituted with saline and formed an opaque
viscid solution that was difficult to administer down the tracheostomy tube. The
reasons for its failure to improve survival and oxygenation due to inactivation are
noted in the previous two chapters. The viscid Pumactant may have blocked some
airways, which would be reflected in poorer Cdyn and static compliance.
Leach et al also found that the artificial, apoprotein free surfactant Exosurf combined
1 7R
with PLV lead to a slightly worse Cdyn than giving PLV alone to preterm lambs.
They administered Exosurfprior to PLV with Perflubron, comparing this group with
PLV alone, Exosurf alone and a control group. They had previously compared the
effects of mixing Perflubron in vitro with various preparations of surfactants
(Exosurf, and also two apoprotein containing surfactants Survanta and Infasurf. They
found no interference by Perflubron in any of the surfactant surface tension reducing
properties. They chose Exosurf as being the more readily available preparation at the
time of the study). Further evidence that the artificial surfactants may block access of
the PFC to the lungs was demonstrated by a 15 minute delay in the effect of
Perflubron following the administration of the Exosurf.
Tarczy-Elornoch and colleagues 1 in their work on excised premature lamb lungs
found an improvement in compliance when pre-treating with the surfactant Survanta
followed by PLV with Perflubron although an even greater improvement was seen
with total liquid ventilation. They attributed this to there being additional sources of
surface tension in the surfactant/PLV group (PFC/lung + gas/PFC + gas/lung albeit
160
that a layer of surfactant helped to reduce surface tension at each of these interfaces)
compared with only PFC/lung in the TLV group. They were also are cautious to
make the point that findings may be specific to the PFC, surfactant and animal
model studied.
In summary, partial liquid ventilation with PF 5080, Curosurf and the combination
of Curosurf/PLV with PF 5080 improves dynamic respiratory system compliance in
saline lavaged rabbits for up to three hours.
Static total respiratory system compliance is improved by Curosurf but not by
Pumactant. This is sustained over a six hour period. The difference in Crs between
Pumactant and Curosurf at 6 hours, which is not noticed in the 6 hour Cdyn figures
may be due to the differing measurement techniques.
These findings may be specific to the surfactant and PFC studied and care should be
exercised before extrapolating this to human use.
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Chapter 6
Computerised tomography studies of Partial Liquid
Ventilation; density distributions on CT scanning comparing
the nebulized route to Partial Liquid Ventilation or control.
Summary
The aim of this chapter was to examine any differences on CT density distribution
between the poured and nebulized routes of administration and that of control
animals.
The CT images of the excised lungs of rabbits, whose lungs had been injured by
saline lavage as previously described, were compared for three treatment groups;
control, partial liquid ventilation with PF 5080 and nebulized PF 5080. The lungs
were divided into three slices cranially to caudally ("apical slice", "middle slice" and
"caudal slice") and also into three zones anteriorly to posteriorly (A-P zones
"anterior", "middle" and "posterior"). The mean attenuation number in Hounsfield
units (HU) was noted for a region of interest (ROI) taken from each area. A
comparison was also made to two normal rabbits that had been neither lung injured
nor intubated and mechanically ventilated.
The radiological density of the normal lungs was less than all three other study
groups. There was also a difference between the control and partial liquid ventilation
groups, as well as the partial liquid ventilation and nebulized groups, but no
difference between the nebulized and control group.
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The CT results confirm the impression that little PF 5080 can be delivered by the
nebulized route using this apparatus. There is a suggestion that PF 5080 is
prevented from reaching the alveoli even by the poured route.
When lung regions within the three major treatment groups were compared, no
significant difference was found. This suggests less of a gravitational and regional
difference than some other studies.
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Introduction.
CT scanning is an established method of assessment and investigation of the lungs in
ARDS 34;115;117. There has been limited use of CT scanning to study the effects and
distribution of perfluorocarbon during liquid ventilation in animal models of
ARDS179; 119.
There had been no CT investigation of nebulized PFC in lung injury, until this
present study.
Methods
A total of 26 young adult female New Zealand white rabbits (10 control rabbits, 6 of
the rabbits treated with PLV and the 10 treated with nebulized PFC) were
anaesthetised, prepared and randomised as described in chapters 3, 4 and 5. At the
end of the procedure, surviving animals were killed with an overdose of general
anaesthetic. For comparison two normal New Zealand white rabbits were killed
without any instrumentation of the airway or inducing lung injury. These were
animals who were left at the end of the study. Under Home Office Regulations such
animals must be humanely killed at the end of a project. Rather than let this tissue be
wasted, the excised lungs of these animals were prepared by immersing in liquid
nitrogen. The original project did not allow financially for a separate control arm of
the study with ten further animals to be included, and the original comparison was to
be between true "control" (but lung injured) PLV and nebulizer treated animals.
Thus some information is included from these normal animals for interest. However
it should be borne in mind that they are a small group of two non-randomised
animals. No more conclusion than that should be drawn from these two animals.
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For simplicity's sake (and due to limited storage for the frozen specimens) it was
decided to compare only control, poured and nebulized groups rather than the
additional combination groups, which may be investigated in further studies at a
later date.
Immediately after death, the trachea was clamped at end-expiration whilst
maintaining the previously applied 4cm H2O PEEP. The lungs were removed en bloc
and immediately immersed in liquid nitrogen. They were then stored at -70°C until
CT scanning.
CT scanning was done with an IGE Medical Systems hi-speed advantage rapid
processing CT scanner (IGE Medical Systems, Milwaukee, USA) using the
following settings: lOOkV, 100mA, pixel size 0.64mm x 0.64mm, 1 mm slice
thickness (thus voxel size 0.64 x0.64 x 1mm), 5mm gaps, 1 second exposure using a
bone algorithm (high resolution) axial acquisition.
Nine control animals, six partial liquid ventilation animals and nine animals given
nebulized PF 5080 yielded suitable specimens for CT examination as well as the two
normal animals.
The excised lungs were scanned in groups of two or three while stored on ice and
referred to only by reference numbers i.e. blinded to which group they came from.
The radiographer who performed the scanning took no other role in the study.
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Figure 16. Key to slices and zones of CT study
Key; Animal in supine position for experiment. Hence
1 Apical slice; Anterior zone
2 Apical slice; Middle zone
3 Apical slice; Posterior zone
4 Middle slice; Anterior zone
5 Middle slice; Middle zone
6 Middle slice; Posterior zone
7 Caudal slice; Anterior zone
8 Caudal slice; Middle zone
9 Caudal slice; Posterior zone
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For each animal representative areas were selected from three anterior to posterior
zones; in the apical slice anterior zone, in the apical slice middle zone, and in the
apical slice posterior zone. The mean radiographic densities within these areas of the
respective anterior, middle and posterior zones were recorded in Hounsfield units
(HU). This process was repeated for the middle and caudal slices (see Figure 16). To
assess the reproducibility of the study, further representative areas were selected at
similar levels twice (designated Reading 2 and Reading 3) several months after the
first review was performed. This was with no knowledge of what the first results had
been.
The mean HU attenuation of a sample of PF 5080 measured on six occasions on the
above scanning settings, was found to be 606 HU (SD 13 HU; n=6).
Results;
The mean HU values of each region of interest (ROI) were noted for each of the 9
areas (apical slice, middle slice, caudal slice each with an anterior, middle and
posterior zone) for each of the 3 study groups and the two normal animals. Due to
fissuring artefact one specimen from the control group and one specimen from the
nebulized group were too badly damaged for meaningful analysis to be performed.
The data from these two animals is therefore not included in the following results.
This left 9 control, 6 partial liquid ventilation i.e. poured , 9 nebulized and 2 normal
animals each with CT densities measured in 9 areas (giving 81, 54, 81 and 18 data
points respectively). This information is shown in Table 16 for the 1st reading. As
the data did not approximate to a normal distribution using the Kolmogorov-
Smirnov test, the Kruskal-Wallis test was used to compare the groups. The statistical
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package used for this was GraphPad Prism™ Version 2.0 (GraphPad Software Inc.,
San Diego, California, USA). Intergroup comparison was made using the Kruskal-
Wallis non parametric test, with Dunn's multiple comparison test. This yielded the
following results; there was a statistically significant difference between Control and
PLV, Control and Normal, PLV and Nebulized, PLV and Normal and Nebulized and
Normal. There was no statistically significant difference between the Control and
Nebulized groups.
Within group comparisons made for Control, PLV and Nebulized groups yielded no
statistically significant differences between any of the lung areas (using the Kruskal-
Wallis non-parametric test with Dunn's multiple comparison test). This implies no
gravitational effect in either the cranial-caudal or anterior to posterior directions.
The information for the 1st, 2nd and 3 rd readings is shown in Table 17.
Table 18 shows the differences between the 1st & 2nd readings, and the 2nd & 3 rd
readings. The Wilcoxon signed rank test (paired) shows that there was no
statistically significant difference between lst/2nd readings compared with 2nd/3rd
reading.
Figure 17 is a scatter diagram of the CT densities at the first reading.
Figure 18 shows a scatter diagram of the distribution of CT densities of all 3
readings for the control, poured PFC, nebulized PFC and normal animals, as well as
a scatter diagram of the differences between the lst/2nd and 2nd/3rd readings.
Figure 19 shows the differences between 1st and 2nd readings as well as the 2nd and
3 rd readings in bar chart format.
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Figure 20 shows the differences in CT densities plotted against mean values for the
1st versus 2nd readings then the 2nd versus 3rd readings.
Examples of the CT images on ice from animals in each group are shown in Figures
21a-c (Control), 21d-f (Poured), 21g-i (Nebulized) and 21j-l(Normal).
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81 54 81 18
Minimum
value (HU)




-71 -14.5 -65 -274




-46 71.50 -47 -156.5
Maximum
(HU)
-24 449 55 -103
Intergroup comparison was made using the Kruskal-Wallis non parametric test, with
Dunn's multiple comparison test. This yielded the following results;
Control vs Partial liquid ventilation (PO.OOl)
Control vs Nebulized (P>0.05)
Control vs Normal (PO.OOl)
Partial liquid ventilation vs Nebulized (PO.OOl)
Partial liquid ventilation vs Normal (PO.OOl)
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Nebulized vs Normal (PO.OOl)
Within group comparisons were also made for the three study groups (Control, PLV
and Nebulized). This compared each lung area with each other again using the
Kruskal-Wallis non-parametric test with Dunn's multiple comparison test. This
found no gravitational effect in either the cranial-caudal or anterior to posterior
directions.
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Table 17. CT densities of Regions of Interest taken from 1st, 2nd and 3rd
readings of treatment groups. * denotes one area, one animal not possible
to obtain a distinct third reading.
Number of Minimum 25% Median 75% Maximum








81 -228 -71 -57 -46 -24
Control 2nd
Reading
81 -224 -54 -44 -36 -22
Control 3rd
Reading
81 -164 -52 -43 -34 -18
Poured Is'
Reading
54 I 00 O -14.5 8 71 449
Poured 2nd
Reading
54 -100 -24 18 72.5 483
Poured 3rd
Reading
53* -68 -15 26 61 409
Nebulized
1st Reading
81 -118 -65 -58 -47 -11
Nebulized
2nd Reading
81 -85 -59 -51 -45 -12
Nebulized
3rd Reading
81 -77 -58 -50 -37 -5
Normal 1st
Reading
18 -326 -274 -201 -156.5 -103
Normal 2nd
Reading
18 -353 -260 -192.5 -150 -94
Normal 3rd
Reading
18 -334 -259.5 -200.5 -169.5 -103
For accompanying scatter diagram to Table 17, see Figure 18.
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Table 18. Difference between 1st/ 2nd and 2nd/3rd Readings (Also see Figures












Median (HU) Value of
Differences
-6 -2.5






i.e. Median difference of a value between 1st and 2nd reading was -6 HU. Median
difference between 2nd and 3rd reading was -2.5 HU. Distribution of differences not
Gaussian (according to Kolmogorov-Smirnov test). Therefore non-parametric used.
Wilcoxon signed rank comparing test differences between Readings 1 & 2 with
differences between Readings 2 & 3.
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Wilcoxon signed rank test (paired) to test null hypothesis that there is no significant
difference between lst/2nd readings compared with 2nd/3rd reading
P-0.087
No statistically significant difference.
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Figure 17. Distribution ofCT densities; 1st reading. Scatter diagram




















































Figure 19. Differences between CT densities 1st & 2nd readings and 2nd &
3rd readings; bar chart format.
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Figure 20. Differences in CT densities plotted against mean values (in HU)
after Bland and Altman180.
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Examples of the CT scans are shown in Figures 21a-c (Control) 21d-f (Poured) 21g-i
(Nebulized) and 21j-l (Normal).
As an additional aside, an example of standard chest x-rays from an animal in the
PLV group is shown for comparison with one from an animal in the control group
(Figure 22). They were taken on similar settings (50kV, 2mA). Despite the fact that
« • 70
PF 5080 contains no bromine or iodine, the atoms said to convey radiodensity , the
presence of PF 5080 obscures the appearance of lung fields. This is shown merely to
underscore the point discussed in chapter 1, that diagnosing other underlying
features such as pneumothoraces or intravenous catheters using standard x-rays, is
difficult through a PFC medium.
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Control Group Apical Slice
Tissue
Figure 21 a
Note tissue in two fragments in surrounding ice.
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Control Group Middle Slice
Figure 21 b
181
Control Group Caudal Slice
Figure 21 c
182
Poured Group Apical Slice
Figure 21 d
Note the intense white density of the PFC on CT scanning.
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Poured Group Middle Slice
Figure 21 e
184
Poured Group Caudal Slice
Figure 21 f
185
Nebulized Group Apical Slice
Figure 21 g
Note the difference in appearance of nebulized slices compared with
the previous 3 slices from the 'poured' group.
Note the similarity to the control group.
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Normal Group Apical Slice
Figure 21 j
Note the generally less dense appearance of the uninjured lungs.
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Normal Group Middle Slice
Figure 21 k
190
Normal Group Caudal Slice
Figure 21 I






First, there was a large capacity for artefact in preparation of samples for this study.
The limited number of other studies which described performing CT scanning on
lung injured animals undergoing PLV, have done their studies in vivo118'119.
However there were insurmountable logistical reasons why this could not be done
here. Home Office regulations allow animal experimentation to be conducted in only
Home Office approved centres. The animal laboratory to which I had access had no
CT scanner in situ. Therefore it was not possible to perform the CT scanning on
intact animals either in life or after being killed but still ventilated.
Furthermore, logistically it would have been prohibitively expensive to perform the
CT scanning at the end of each procedure on fresh lungs. Thus the lungs were frozen
in liquid nitrogen and scanned en masse at the end of the project.
This did introduce the possibility of preparation artefact particularly Assuring of the
lung on introduction to the liquid nitrogen. For this reason one specimen from the
control group and one specimen from the nebulized group, which were both too
badly fissured to subject to CT scanning, were not included in the above results.
As the lungs were frozen in one phase of respiration (end-expiration) it is not
possible to comment on whether there was any cyclical variation in the distribution
of the PFC 118119. Furthermore, the process of excising the lungs and lowering them
into liquid nitrogen could have introduced artefact or that the process of freezing
itself introduces some change of distribution.
Second and third readings taken from approximately similar areas of lung were taken
to test agreement (e.g. how much the 1st reading differs from the 2nd or the 2nd from
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the 3rd) and repeatability of the method (degree of variation on repeated measures on
the same subject)180. As the raw CT density distribution as well as the difference
against mean plots demonstrate, (Figures 17, 18 and 19) there seems to be no
significant difference. The median difference comparing similar areas in the same
rabbit between 1st and 2nd readings was -6HU. The median difference comparing
similar areas in the same rabbit between 2nd and 3rd readings was -2.5 HU i.e. very
small in both cases. There was also no statistically significant difference
demonstrable on the Wilcoxon test. Thus the areas selected demonstrated acceptable
agreement and repeatability.
There was no difference in densities between the control group and the nebulized
PFC. This suggests that negligible amounts of PFC are deposited in the lungs with
this method of administration.
In contrast, there was a significant difference between the poured and nebulized
groups.
The CT density ofpure PF 5080 is approximately 606 HU (standard deviation ± 13)
on the scanner settings above. For comparison air has an attenuation value in HU of
-1000, water of 0 HU and bone +1000 HU 117. The CT number can be considered as
a function of the physical density and electron density 181. This may differ slightly
from the weight/volume density e.g. physical density of PF 5080 in terms of
weight/volume is 1.76g/ml (3M's data sheet). According to Mull181 an
approximation of the physical density of a substance can be calculated by computed
tomography by the following formula;
CT number =K([p-pw)]/pw where
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K is a magnifying constant usually set at 1000
p. is the linear attenuation coefficient of the pixel (or voxel) being studied
and pw is the linear attenuation coefficient of water. Then for PF 5080 with a CT
number of 606, and assuming a density for water of 1, the formula can be rearranged
as follows;
p= 606/1000+ 1= 1.6.
Thus the linear attenuation coefficient of PF 5080 is 1.6. Therefore, the radiological
density of a voxel 1/3 filled with gas, 1/3 filled with tissue or oedema, and 1/3 filled
with PF 5080 would be
Gas 0.33 x 0 gram mass = 0
Fluid/Tissue 0.33 x 1 gram mass = 0.33
PF 5080 0.33 x 1.6 gram mass (as far as electron absorbing
capacity is concerned) = 0.42
Total mass (electron absorbing capacity) =0.75 gram
Thus HU in this voxel =1000 [0.75-1/1)]
= -250 HU
(See Figure 23a and 23b)
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Figure 23a
Schematic representation of a voxel completely filled with PF 5080
CT attenuation = 606 HU.
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Figure 23b. Schematic representation of a voxel 1/3 filled with gas, 1/3 filled
with tissue/fluid, and 1/3 filled with PF 5080. Total CT number for this voxel
=-250 HU (see text).
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In short, a small amount of a substance with such a drastically different CT
attenuation number than PF 5080, can radically alter the CT attenuation number of a
lung region or voxel. As the distribution of the original values in Figure 17 and also
in Tables 16 and 17 demonstrate, the poured group had the greatest (449 HU). This
is in the group whose lungs had been supposedly fdled to FRC with PF 5080. This is
much less than expected and implies that there is the presence of some other less
radiodense substance in the alveoli "diluting" the attenuation of the PFC such as
tissue or fluid, or gas. This would be consistent with oedema or gas lying within the
alveoli. This is essentially a partial volume effect "in reverse"116, where instead of a
dense substance elevating the mean HU attenuation within a voxel, there is a less
dense substance reducing the HU attenuation. In Kaiser et al's study investigating
the effects of PEEP superimposed upon PLV in vivo, opacities representing a
combination of PFC and oedema/lavage fluid were clearly seen in the airways 119.
With time the aqueous fluid will appear to float on top of the denser PFC, as noted
in other studies 12°. If an airway were to be obstructed, this would inhibit access of
PF 5080 to the lung periphery. The lung region beyond this obstruction would
presumably reflect the HU attenuation of collapsed lung (circa 1 HU) rather that of
PF 5080.
Alternatively it may be that the lungs had not been completely filled due to pockets
of gas trapped "under" the level of meniscus seen in the tracheostomy tube. Fuhrman
suggested in early work on partial liquid ventilation that a bubble of gas may be left
at the top of the alveoli at end-expiration82. The exact distribution which PFC takes
up within alveoli is still debated. A possible elaborate explanation has been given by
Tarczy-Hornoch's group (see Figure 24a and 24b) '.
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They suggest that the distribution within the alveolus may be the net effect of surface
tension vectors determined by the interface between PFC/lung, gas/PFC and
gas/lung i.e whether the PFC has a lentiform structure or whether it forms a lining
layer within the alveolus.
Figure 24a. PFC forms lens shaped bubble within alveolus1
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Figure 24b Interaction of surface tensions forces PFC into a rim lining the
inside of the alveolus.
A further explanation would be that the quoted figures for the FRC of rabbits
149,170,182
were underestimates, although this would not explain the clearly seen
menisci of PFC in the endotracheal tube at zero PEEP.
The study also demonstrated no gravitational effects within study groups, something
which rather contradicts Gattinoni et al's work on CT scanning of lungs in ARDS, as
well other radiological studies (both CT and conventional radiograms) in the
presence of PLY 12°;121-
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There are some differences between these other studies and the present study which
may explain these findings. First, Gattinoni's group studied intact patients with
ARDS, removing the confounding preparation artefacts compared with this study.
Second, this study dealt with small animals in comparison to either patients or larger
animals with correspondingly larger thoraces. It may be that relatively little collapse
is induced by the weight of overlying lung when the dimensions of the thorax are of
the order of 5cm compared with several times larger in the sheep118 or humans.
Alternatively more animals may be required to make this difference obvious
although the number of subjects in the study groups in this study were comparable to
those in the other studies.
In summary this ex-vivo CT scanning study of density distributions showed no
difference in the density distributions of control animals and animals given PF 5080
by ultrasonic nebulizer. There was a significant difference in CT attenuation values
between poured and nebulized PF 5080, and PLV and control animals. The study
also implies there is incomplete filling of the lungs with PF 5080 even when poured
volumes equivalent to the FRC of the rabbit are administered.




Summary and General Discussion
The work described in this thesis was one of the first attempts to give PFC by
nebulisation to treat acute lung injury. When the project was being drafted no other
group had attempted this, although in the interim there have been groups who have
published work reporting vaporised or aerosolized PFC 155;161;183_
Summary with Future Possibile Directions of Research
The broad outcomes studied in this project were survival, oxygenation, lung
mechanics and the CT density distributions. These may be interrelated as follows.
It is reasonable to assume that unalleviated hypoxia may cause shortened survival134.
Four therapies (Poured PFC i.e. PLV, Curosurf, Pumactant/PLV and Curosurf/PLV)
caused significant improvement in oxygenation. This was reflected in an
improvement in 12 hour survival for Poured PFC and the combination of
Pumactant/PLV. The other two therapies could arguably be showing a trend towards
improved survival hidden by the relatively small numbers or the conservative nature
of the Bonferroni test. However it may be that the rapidity of action of Curosurf
either alone, or in combination may have deleterious effects negating some of the
positive effects of improved oxygenation. This is discussed in greater detail below.
The same four therapies which improved oxygenation, had broadly similar effects on
improving Cdyn. Three of these therapies (PLV, Curosurf and the combination of
Curosurf /PLV) caused statistically significant improvements. Pumactant/PLV
showed a trend towards improvement but was not statistically significant. This may
202
reflect as yet undetermined interactions between the differing surfactant preparations
and PF 5080 which affect oxygenation and lung mechanics in differing ways.
Further work to discover the modes of action of PFC is worthwhile since there does
seem to be a difference in the maximum effect for improvement in lung mechanics
compared with the improvement in oxygenation158. This lends credence to the theory
that PFC is coating the alveoli124;155 and once it has coated the alveoli no further
improvement in lung mechanics may be obtained, as PFC has a constant surface
tension. In contrast, improvement in oxygenation is caused either by maintaining
alveoli open79, or by an effect on ventilation/ perfusion ratios81. As more alveoli are
maintained open, a greater improvement in oxygenation occurs. However there may
be differing effects on ventilation/ perfusion matching which depend upon the PFC
used. This requires clarification.
Some of these therapies, particularly those containing Curosurf, may have worked
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too well (or more exactly too rapidly) resulting in overdistention of lung and
pneumothorax, detracting from their positive effects. This could explain an
improvement in compliance but not in survival.
It could perhaps be argued that the Pumactant/PLV group's less significant
improvement in lung mechanics was an ideal compromise, allowing a good response
in oxygenation but not causing such a spectacular (and damaging) distention of lung.
Another interpretation of the failure of Pumactant/PLV to improve Cdyn, yet
apparent success in improving survival and oxygenation was that the Pumactant had
no effect on at all, and the improvement in oxygenation and survival seen was purely
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due to the PLV. The Pumactant may have inhibited PF 5080 from reaching some
airways as alluded to in chapter 5. This would explain why there was no statistically
significant improvement in Cdyn.
The fact that there was no statistically significant difference in the incidence of
pneumothorax between groups (chi squared test) may just reflect relatively small
numbers, or in some groups death rapidly from hypoxia before pneumothorax could
develop.
In addition to studying the effects of combinations of PF 5080 with the surfactants
Pumactant or Curosurf mentioned above, this work also studied the effects of the
artificial surfactant Pumactant or the natural surfactant Curosurf given as a solitary
treatment on survival, oxygenation, Cdyn, and Crs.
Pumactant failed to have any effect on survival, oxygenation and either Cdyn or Crs
in the current study.
A trial published while this project was being completed, compared Pumactant with
Curosurf for the treatment of respiratory distress syndrome of the newborn was
1 84
stopped prematurely due to an excess of deaths in the Pumactant group .
It is recognised that the natural surfactants have a more rapid onset of action than the
• • 177• 18S •
synthetic non-surfactant protein containing surfactants ' . This very rapid onset
may cause undesirable effects as discussed above. Pumactant may have shown a
greater effect if this study was repeated but over a longer period of time, such as 24
hours. However this presupposes a change to Home Office regulations, and that the
animals would survive a prolonged period with critical oxygenation.
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Alternatively the saline lavage model may be an inappropriate model to use when
studying Pumactant.
The difference between Curosurf s improvement in oxygenation, Cdyn and Crs and
Pumactant's failure may be explained by the presence of surfactant proteins and their
increased resistance to inactivation in the presence of injured lung129'132'175'176.
Certainly there is scope for further work to investigate what actually happens to
exogenously administered surfactant in humans with acute lung injury.
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The thesis also investigated the effects of nebulized PFC on survival, oxygenation,
Cdyn and CT density distributions.
This project found that nebulized PF 5080 had no effect on these four outcomes.
This would be consistent with no PFC actually being delivered to the alveoli. This is
in contrast to the positive effects seen in subsequently published papers using other
apparatus.
It would be interesting to repeat this study with a differing mechanical ventilator,
perhaps one using a circle system which re-circulates fresh gases (as used by Bleyl's
group)155 or an aerosol jet injector (similar to that used by Kandler et al)183. My
project used the SLE 250 which has a continuous flow bias, because of its ready
availability to me. This may waste a large proportion of the fresh gas flow. A further
study may perhaps look at the proportion of PFC deposited in the lungs by a
different method (perhaps by radio-labelling). Alternatively another form of
nebulizer may be used.
Another explanation of the differing outcomes is that Bleyl and Kandler's studies
used other PFC compounds (Perfluorohexane and Perflubron). Projects designed to
study the differing effects of PFC (particularly with differing vapour pressures if a
nebulized or vaporised route is considered) should continue to find the most
appropriate PFC to use.
The CT density arm of the study did not just yield interesting results for the
nebulized group. Another noteworthy outcome was that PFC did not seem to reach
all parts of the lung apparently submerged under PF 5080 in the PLY group. This
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was presumed due to atalectatic lung preventing PFC reaching these areas of
collapse.
Future Uses of PLV with Perfluorocarbons.
One must be cautious about implying that results that occur in animal models in the
research laboratory will translate directly into clinical practice. The future of partial
liquid ventilation will be largely determined by the results of the current on-going
trials.
PF 5080 was substantially cheaper than a single dose of either preparation of
surfactant but seemed better than Pumactant at improving oxygenation and lung
mechanics. It is equally as good as the more potent surfactant (Curosurf) at
improving oxygenation and lung mechanics, and better than both surfactants in
improving survival, at least over the relatively short period of the study.
After further studies PFC may prove to be cheaper ways of applying surface active
agents in ARDS.
This study did not concern itself with the disease altering potential of PFC. A study
specifically designed to explore the effects of PFC on lung inflammation and
histology (as mentioned in chapter 2) would be timely.
The place for liquid ventilation may be in specialist centres for the group ofpatients
who are failing to improve on "best conventional" management or for whom
permissive hypercapnia is (relatively) contraindicated (such as raised intracranial
pressure or ischaemic heart disease) or in whom other novel therapies such as
surfactant administration have failed. PLV has been suggested as a means of
delivering drugs to the respiratory tract 186 187- There has been a small amount of
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work comparing PLV use in combination with other treatments used in ARDS (such
as inhaled nitric oxide)123.
PLV can improve oxygenation and lung mechanics and it is worth preserving as part
of the armamentarium of novel therapies in ARDS for selected patients. Delivery as
either an aerosol or by vapour is as yet an underinvestigated field worth exploring.
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